SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions August inventions list 08/10

20100215571 - Polymer based radionuclide containing particulate material: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.... Agent: Merchant & Gould PC

20100215572 - Methods of treatment using ldcam: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.... Agent: Immunex Corporation Law Department

20100215573 - Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well... Agent: Merck

20100215574 - Process for producing an injectable medicament preparation: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance... Agent: Ropes & Gray LLP

20100215577 - Compositions and methods for visualizing and eliminating cancer stem cells: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial... Agent: Howrey LLP - East

20100215576 - Diagnosis and treatment of neuroectodermal tumors: The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas,... Agent: Choate, Hall & Stewart LLP

20100215575 - Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors: The present invention is directed to methods and compositions for the treatment and diagnosis of neoplastic tumors. The inventive methods generally include systemic (e.g., intravenous) administration of a chloroxotoxin agent that may or may not be labeled.... Agent: Choate, Hall & Stewart LLP

20100215578 - Catalytic radiofluorination: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100215579 - Phen-naphthalene and phen-quinoline derivatives and their use for binding and imaging amyloid plaques: This invention relates to methods of imaging amyloid deposits, radiolabeled compounds, and methods of making radiolabeled compounds useful in imaging amyloid deposits. This invention also relates to compounds and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits and methods of delivering therapeutic agents... Agent: Woodcock Washburn LLP

20100215583 - Cell nucleus-entering compositions: A pharmaceutically acceptable composition and method for entering a cell nucleus utilizes a cell nucleus-entering polypeptide including at least one of amino acid sequence LKKTET (SEQ ID NO: 1), amino acid sequence LKKTNT (SEQ ID NO: 2) or amino acid sequence KSKLKK (SEQ ID NO: 3), or a conservative variant... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100215580 - Compositions and methods for enhancing transport through mucus: The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances.... Agent: Ropes & Gray LLP

20100215581 - Contrast agents for detecting prostate cancer: The invention relates to contrast agents for diagnosing prostate cancer in a human or animal being. These contrast agents are compounds comprising a targeting module that is capable of interacting with a prostate cancer-specific molecular marker and a detectable unit. The invention also concerns the use of such compounds for... Agent: Philips Intellectual Property & Standards

20100215582 - Liposome and method for producing liposome: It is intended to provide a liposome preparation which is a liposome, has a lipid bilayer membrane composed of an inner membrane constituted by a lipid including one or more types of functional lipids (a lipid capable of chemically interacting with another compound such as a charged lipid, a polarizable... Agent: Cantor Colburn, LLP

20100215584 - Compositions and methods of modulating the taste and smell receptors and screening methods therefore: The present invention relates to modulation of the perception of either taste or smell through modulation of the activity of GRKs which regulate the desensitization process of the taste and smell receptors. By the process of either inhibiting or enhancing GRK activity at the receptor site a modulation in perception... Agent: Passe' Intellectual Property, LLC

20100215586 - Novel method for preparing nanoparticles covered with a gem-bisphosphonate stabilizing layer coupled to hydrophilic biodistribution ligands: A novel method for preparing nanoparticles for medical imaging, including a metal core, an organic stabilizing layer containing gem-bisphosphonate compounds and at least one hydrophilic biodistribution ligand.... Agent: Young & Thompson

20100215587 - Materials and methods for mri contrast agents and drug delivery: A material useful as a MRI contrast agent used for medical imaging, drug delivery platform or other functions are provided as a class of non-gadolinium and non-iron oxide based materials that comprise Prussian blue materials or analogue materials. The materials may be used as T1-weighted and/or T2-weighted MRI contrast agents... Agent: Hahn Loeser & Parks, LLP

20100215585 - Dyes and precursors and conjugates thereof: Novel dyes, precursors to novel dyes, and conjugates of the novel dyes are disclosed, as well as methods of making and using the same.... Agent: Fish & Richardson PC

20100215589 - Carbamate stereoisomer: v

20100215588 - Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system: The present invention relates to methods of treating respiratory disorders of all types, including pulmonary disorders, by delivering inhibitory nucleic acid molecules directly to the respiratory system. siRNAs or other nucleic acids are delivered to the lung/respiratory system for the treatment of disease.... Agent: Cooper & Dunham, LLP

20100215590 - Micronization method: The invention relates to a method for producing a micronized, virtually anhydrous form of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide, said form per se, and the use thereof for producing a medicament, especially a medicament having an anticholinergic effect.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100215591 - Antimicrobial peptide, compositions, and methods of use: The present invention provides antimicrobial peptides that exhibit a broad range of antimicrobial activity to gram positive and gram negative bacteria, as well as fungi, mold, and virus. The antimicrobial peptide of the invention is a cationic peptide, and may contain an HIV-TAT or reverse HIV-TAT sequence, or derivative thereof.... Agent: King & Spalding

20100215592 - Composition for oral cavity: (wherein, R represents a substituted or unsubstituted, linear or branched alkyl group having from 6 to 18 carbon atoms, G represents a galactose residue, m stands for an integer of from 0 to 200, and n stands for an integer of from 1 to 30); and a coaggregation inhibitor of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100215593 - Ionic complexes: The present invention provides a phosphopeptide or phosphoprotein (PP) stabilised amorphous calcium phosphate or amorphous calcium fluoride phosphate complex having a calcium ion greater than about 30 moles of calcium per mole of PP... Agent: Merchant & Gould PC

20100215596 - Aqueous meta-stable oil-in-water emulsions: Disclosed are aqueous o/w emulsions with the ability to invert into w/o emulsions by introduction of mechanical energy, comprising (a) oil components, (b) w/o emulsifiers, (c) cationic surfactants, (d) actives, and (e) cationic-compatible stabilisers. The emulsions are useful for making cosmetic or pharmaceutical compositions, particularly sprayable sun care emulsions.... Agent: Fox Rothschild LLP

20100215598 - Composition comprising a sucrose ester and a polyglycerol ester: Composition containing an aqueous phase, a lipophilic compound and an emulsifying system containing a fatty acid ester of sucrose and a fatty acid ester of polyglycerol, and to its use in the cosmetics field, in particular for cleansing and/or for removing makeup from keratin materials.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100215600 - Compositions comprising a uv-absorbing chromophore: wherein X1 and X2 are the same or different, and at least one of X1 or X2 is a functional group that bonds with the compound comprising at least one UV-absorbing chromophore, and b+f≧2, Y comprises an 0, N, or S that is substituted or unsubstituted, each a, b, c,... Agent: Conley Rose, P.C.

20100215599 - Method of making up with light-sensitive makeup by applying a base layer and a kit for implementing such a method: e

20100215595 - Personal care compositions containing silicone-organic gels from polyalkyloxlene crosslinked silicone elastomers: Silicone organic gels and ge! paste compositions are disclosed containing a silicone organic elastomer in a carrier fluid. The silicone organic elastomer is a reaction product of a linear or branched organohydrogensiioxane, an α, ω-unsaturated polyυxyalkylene, and a hydrosilylation catalyst. The silicone organic elastomer is particularly useful to gel organic... Agent: Dow Corning Corporation Co1232

20100215597 - Self-tanning agents and dehydroascorbic acid or a monomeric, polymeric or isomeric derivative thereof for artifically coloring the skin: l

20100215594 - Tyrosinase inhibitors: The invention relates to compounds of the formula I where the substituents AA1, AA2, o and R have a meaning indicated in claim 1, and to the salts and solvates and mixtures thereof, to a process for the preparation thereof, preparations and the use thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20100215601 - Glow in the dark nail polish: Glow in the dark nail polish for individuals who desire to have something more than their everyday nail polish selection. Applying a polish that will glow in the dark is not only different then the polish offered today, but it also would allow the user to enjoy another side of... Agent: Sandra L. Abrahamian

20100215602 - Oily solid cosmetic material: o

20100215603 - Body surface protecting composition: A body surface protecting composition, comprising at least one type of multi-chain multiple hydrophilic group-type compound having two or more hydrophobic groups and two or more hydrophilic groups in the molecule, which has an excellent effect of accelerating the recovery of the barrier function of skin and hair and preventing... Agent: Birch Stewart Kolasch & Birch

20100215606 - Conditioning composition for hair comprising optical brightener: The present invention is related to a conditioning composition for hair comprising optical brightener. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after use of cleansing compositions. The preferred optical brightener is disodium... Agent: Londa, Bruce S. Norris Mclaughlin & Marcus, Pa

20100215605 - Solid cosmetic composition for application to keratin fibres: A cosmetic composition for caring for and/or making up keratin fibres, in stick form, which can be applied dry: (i) which is in the form of an emulsion comprising a fatty phase dispersed in an aqueous phase, the said fatty phase comprising at least one wax, (ii) which has a... Agent: Oliff & Berridge, PLC

20100215607 - Cosmetic composition: A cosmetic composition comprising a first polymer being a cationic polymer, a second polymer selected from chitosan, salts and derivatives thereof, and a cosmetically acceptable carrier. This composition is suitable for achieving long-lasting hold, high hair-setting properties and exhibiting satisfactory consistency/rheology altogether with exhibiting appealing characteristics.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100215608 - Hair setting composition: The present invention relates to hair setting compositions comprising the combination of a special polyurethane and of a vinylpyrrolidone homo- or copolymer, and to the use of said combination for the preparation of hair setting compositions.... Agent: Connolly Bove Lodge & Hutz, LLP

20100215609 - Styling agents giving a high degree of hold in humid conditions: wherein n is 1, 2 or 3 as the number of methylene entities; b) and at least one acrylate polymer B, which is different from copolymer A, selected from b1) polyacrylic acid and/or b2) copolymers of methacrylic acid with acrylamidopropane sulfonic acid and/or b3) copolymers of acrylic acid with methacrylic... Agent: Henkel Corporation

20100215604 - Cosmetic compositions with chitosan and silicone elastomers: Hair treatment compositions comprising 0.05 to 5% by weight of at least one chitosan and/or chitosan derivative and 0.05 to 5% by weight of at least one elastomeric silane or siloxane with quaternary ammonium groups in the molecule advantageously incorporated into the hair treatment compositions, significantly improving fullness, volume and... Agent: Henkel Corporation

20100215610 - Process compositions and production of acyl alkylisethionate compositions: Methods and compositions are provided for forming ester based compositions. The ester based compositions may be used in consumer products. In one aspect, a method is provided for producing acyl alkylisethionate esters by the esterification of a sulfonate composition having two or more sulfonate isomers with fatty acid(s). In another... Agent: Huntsman Petrochemical LLC

20100215611 - Use of phosphoric triamides in toilets: The present invention describes the use of phosphoric triamides in toilets.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100215612 - Odor-controlling bodily fluid absorber: e

20100215613 - Pva particle for temporary embolic material and production process thereof, and temporary embolic material: A temporary embolic material for blood vessel which can embolize a blood vessel in a living body and is used for the temporary embolization of the blood stream. More specifically, disclosed is an embolus-forming material comprising a specific PVA particle which can be used for the closure of the inner... Agent: Antonelli, Terry, Stout & Kraus, LLP

20100215617 - Enhanced medical implant: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth... Agent: Taft, Stettinius & Hollister LLP

20100215614 - Enterostatin as inhibitor of angiogenesis: It has been discovered that enterostatin inhibits angiogenesis in an in vitro adipose tissue angiogenesis model. In concentrations from about 10−6 to about 10−9 M, enterostatin effectively blocked the angiogenic response. Enterostatin will be effective in treating noncancerous and cancerous diseases that involve an increase in angiogenesis, e.g., rheumatoid arthritis,... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20100215616 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100215615 - Immunocytokines for cancer treatment in combination with chemotherapeutic agents: This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.... Agent: Dann, Dorfman, Herrell & Skillman

20100215618 - Novel compounds - 644: wherein R1, R2, R3, R4, R5, R6 and L are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of... Agent: Astrazeneca R&d Boston

20100215619 - Hla peptide therapy: The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100215620 - The co-culture method of sphingomonas sp. bacterial strain and aspergillus sp. fungus strain, new anti-cancer and antibiotic glionitrins derived from this co-culture method, and pharmaceutical composition containing glionitrins or pharmaceutically accepta: The present invention relates to a co-culture method of Sphingomonas sp. bacterial strain and Aspergillus sp. fungus strain, in which the novel Sphingomonas sp. bacterial strain KMK-001 is cultured in a liquid medium and the novel Aspergillus sp. strain KMC-901 separately cultured in another liquid medium is added to the... Agent: Lucas & Mercanti, LLP

20100215626 - Mrsa decolonization kit (mdk): The MRSA Decolonization Kit, or MDK, is a unique process available in a single kit to eliminate MRSA from individuals who have recently suffered an invasive infection from the potentially deadly bacteria and strengthen their body's ability to prevent recurrent infection. The kit provides patients with everything they need to... Agent: Brian Murphy

20100215627 - Atopy cure baby dry milk with green tea and lactobacillus: Provided is a prevention and treatment of baby atopy using green tea and lactobacillus digestives. By addition of 0.02˜1.3 wt % of green tea, and for the purpose of preventing side effects from green tea and increasing curative efficacy, addition of 0.15˜10 wt % (0.009˜0.8 wt % on pure lactobacillus... Agent: Ipla P.A.

20100215630 - Plant-derived protectants against ultraviolet light: The present invention relates to plant extracts and formulations and kits thereof that protect insect microbial agents against ultraviolet irradiation. The invention further relates to methods of treating plants that has been damaged by an insect and/or protecting plants against insect damage.... Agent: Myers Bigel Sibley & Sajovec

20100215621 - Recombinant adenoviruses capable of regulating angiogenesis: The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral ITR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc... Agent: The Nath Law Group

20100215623 - Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100215625 - Efficient preparation of naphthoquinone anticancer active ingredients: One of the problems to be resolved by the present invention is to stably and sustainably produce active ingredients contained in Bignoniaceous plants of which a mass production is difficult in a conventional manner. The present invention relates to a method for efficiently preparing an anticancer active ingredient NQ801 by... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100215624 - Pharmaceutical compositions for treating rheumatoid arthritis comprising semi-mature dendritic cell: The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis... Agent: Clark & Elbing LLP

20100215622 - Treatment of immunosuppression-related disorders: Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100215628 - Method for preparing cell populations with anti-tumor immune response activity: The invention provides a method for preparing cell populations with anti-tumor immune response activity, which includes co-culturing tumor and mononuclear cell in a three-dimensional cell culture device, separating and amplifying the cell populations with anti-tumor immune response activity from the cultures. The present invention, at the same time, discloses the... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100215629 - Treatment of tumors using t lymphocyte preparations: The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100215631 - Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof: The present invention relates to nutritional or pharmaceutical compositions comprising lactoferrin and glycine with an anti-inflammatory activity suitable for patients with an inflammatory disease.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100215632 - Biomarkers of sirtuin activity and methods of use thereof: Provided are methods for monitoring sirtuin modulation in a subject, for example, during therapeutic treatment with a sirtuin modulating compound. The methods involve determining the expression level of one or more sirtuin biomarkers in a biological sample from the subject. Also provided are methods for identifying compounds that modulate the... Agent: Ropes & Gray LLP

20100215633 - Method for feeding dairy cows and dairy goats supplements to increase the c2 hxroylated estrogen (c2) to c16 hydroxlated estrogen (c16) ratio secreted in their urine: A feed supplement for dairy cows and goats containing various combinations of whole soy, muscadine grapes, Kudzu leaves, brassica group vegetable and or their chemical constituents designed to shift estrogen metabolism towards favorable estrogen chemistry.... Agent: Robert D. Bibb, M.d.

20100215634 - Visfatin therapeutic agents for the treatment of acne and other conditions: The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions.... Agent: Fulbright & Jaworski, LLP

20100215635 - Small molecules to induce weight loss or to reduce weight gain: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds alone or in combination with alkaline phosphatase or other weight loss-inducing drugs or methods to reduce or reverse excess weight gain and obesity as well as reduce the risk of development and help treatment of diseases and... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100215636 - Peptides derived from plasminogen activator inhibitor-1 and uses thereof: The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.... Agent: Winston & Strawn LLP Patent Department

20100215637 - Agent for the treatment of hormone-dependent disorders and uses thereof: The present invention relates to novel agents that are useful for treating hormone-dependent disorders. In particular, the present invention relates to A method of modulating a nuclear receptor in vivo comprising the step of administering to a subject in need thereof A nuclear receptor modulating agent comprising a compound or... Agent: K&l Gates LLP

20100215644 - Analysis of nodes in cellular pathways: An embodiment of the present invention is a method for measuring activity of cell pathways, such as the cell cycle pathway and correlating the resulting profile to phenotypes. The resulting correlations are useful in diagnosis, prognosis, selection and development of drug treatment regimens, and drug screening applications.... Agent: Wilson, Sonsini, Goodrich & Rosati / Nodality, Inc

20100215643 - Anti-infective functionalized surfaces and methods of making same: Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.... Agent: Gibson & Dernier LLP

20100215639 - Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof: Infection by Chlamydia pneumoniae has been identified as a risk factor associated with the pathogenesis of certain chronic intraocular disorders, for example, age-related macular degeneration. The invention provides methods of identifying individuals at risk of developing chronic intraocular disorders, and methods of delaying and/or preventing the onset of such chronic... Agent: Goodwin Procter LLP Patent Administrator

20100215645 - Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods... Agent: Celera Corporation

20100215646 - Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo) containing different lengths of palindromic segments: The invention provides a palindromic immune modulatory nucleic acid. The invention also provides methods for generating, enhancing and modifying the immune response caused by palindromic immune modulatory compounds used for immunotherapy applications... Agent: Preti, Flaherty, Beliveau & Pachios, LLP

20100215640 - Method for inhibiting cellular activation by insulin-like growth factor-1: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit... Agent: Myers Bigel Sibley & Sajovec

20100215638 - Method for treatment of prostate cancer and screening of patients benefiting from said method: The invention relates to a method for treating ERG-positive prostate cancer patients with an agent counteracting one or more ERG-associated genes and/or manipulating of one or more ERG-related pathways, optionally in combination with an androgen deprivation therapy. Furthermore, the invention concerns methods for screening prostate cancer patients which may benefit... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100215641 - Screening method for compounds that reduce er stress: The present invention relates to a cell comprising an Endoplasmic Reticulum (ER) stress element operably linked to a reporter element and an exogenous gene encoding a protein that induces ER stress. Methods of screening using the modified cell, constructs used in the modified cell, the candidate agents identified by the... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100215642 - Synthetic rna-based agonists of tlr7: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100215647 - Immunological compositions as cancer biomarkers and/or therapeutics: The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.... Agent: Fulbright & Jaworski L.L.P.

20100215655 - Angiogenesis-inhibiting chimeric proteins and the use: The present invention is directed to DNA sequence encoding angionenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.... Agent: The Nath Law Group

20100215649 - Antibodies for norovirus: Norovirus antigen peptides are described having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-16, or fragments thereof. Such peptides can be used in the preparation of antiviral therapies such as vaccines, methods of preparing antibodies to the antigen peptides, methods of using the peptides... Agent: Leydig Voit & Mayer, Ltd

20100215648 - Detecting agent and therapeutic agent for highly malignant breast cancer: The detection agent for high malignancy breast cancer of the present invention includes an antibody against collagen XIV, or a variant or derivative or fragment of the antibody. The therapeutic agent for high malignancy breast cancer of the present invention includes a conjugate of an anticancer drug and an antibody... Agent: The Webb Law Firm, P.C.

20100215651 - Humanized antibodies that bind to cd19 and their uses: The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a... Agent: Kaplan Gilman & Pergament LLP

20100215650 - Methods of treating dementia using a gm-csf antagonist: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical... Agent: Townsend And Townsend And Crew, LLP

20100215653 - Methods of treating neoplastic, autoimmune and inflammatory diseases: Methods of treating cancer and autoimmune and inflammatory diseases are provided.... Agent: Townsend And Townsend And Crew LLP

20100215654 - Methods of treating osteoarthritis with il-6 antagonists: The present invention provides for methods of treating osteoarthritis with IL-6 antagonists such as IL-6 antibodies.... Agent: Pharmacia Corporation C/o Pfizer Inc.

20100215652 - Nicotinamide derivates useful as p38 inhibitors: e

20100215656 - Deletions in domain ii of pseudomonas exotoxin a that remove immunogenic epitopes: The invention provides mutated, cytotoxic forms of Pseudomonas exotoxin A (PE) comprising a furin cleavage sequence conjugated or fused directly to residues 395-613 of PE or variants of that sequence. These minimal forms of PE are smaller than previous cytotoxic forms of PE, reduce non-specific toxicity, and reduce immunogenicity due... Agent: Townsend And Townsend And Crew, LLP

20100215657 - Methods and compositions using klotho-fgf fusion polypeptides: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such... Agent: Novartis Institutes For Biomedical Research, Inc.

20100215659 - Functionalized surgical adhesives: A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair,... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20100215658 - Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100215660 - Kruppel-like factors and fat regulation: Disclosed herein are methods and cell lines used in fat regulation. The methods and cell lines incorporate Krüppel-like factors including, without limitation, klf-1 and klf-3.... Agent: K&l Gates LLP

20100215661 - Nicotinamide derivates useful as p38 inhibitors: s

20100215662 - Anti-influenza m2e antibody: Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.... Agent: Los Alamos National Security, LLC

20100215664 - Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6 -mediated signalling: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as... Agent: Wolf Greenfield & Sacks, P.C.

20100215666 - Il-17 antagonistic antibodies: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g.... Agent: Novartis Corporate Intellectual Property

20100215663 - Methods and compositions for regulation of neurological conditions: The invention relates to methods and compositions for regulation of neurological conditions. In particular, methods and compositions for the modulation of the chemokine receptor 1 (CX3CR1) and its ligands are described.... Agent: Casimir Jones, S.c.

20100215665 - Mixed lineage kinases and metabolic disorders: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods... Agent: Fish & Richardson PC

20100215667 - Methods and compositions of treatment for modulating the immune system of animals: Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal serum can modulate serum IgG levels for treatment in such things as diminished immune capacity, intestinal... Agent: Schwegman, Lundberg & Woessner, P.A.

20100215668 - Methods for the treatment or prevention of hemorrhagic conditions: The present invention relates to a method for treatment or prevention of a hemorrhagic condition in a patient by administering plasminogen activator inhibitor-1 (“PAI-1”) and/or an inhibitor of deubiquitinating enzyme CYLD (“CYLD”) to a patient. Pharmaceutical compositions that include one or both of PAI-1 and an inhibitor of CYLD are... Agent: Nixon Peabody LLP - Patent Group

20100215669 - Anti-cd79b antibodies and immunoconjugates and methods of use: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Arnold & Porter LLP (24126) Attn:IPDocketing Dept.

20100215671 - Combination therapy with antibody-drug conjugates: Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided.... Agent: Townsend And Townsend And Crew LLP

20100215670 - Immunotoxin fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers: Novel conjugates are disclosed which comprise (a) a ligand that binds to a surface molecule on a target cell, such as a cancer cell; (b) an effector molecule that is to be delivered into the cell, such as a toxin; and (c) a linker sequence that couples the ligand and... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100215674 - Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination: With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected... Agent: Knobbe Martens Olson & Bear LLP

20100215673 - Method for treating inflammation and controlled-release material capable of providing same: The present invention relates to methods for treating inflammation associated with bone, joint or connective tissue and an implantable controlled-release material capable of providing these anti-inflammatory activities. In particular, the present invention relates to a method for reducing inflammation in a subject's tissue comprising the step of implanting a material... Agent: Bell & Associates

20100215672 - Preparation process and utilization of poncirus compositions having anti-allergic and antianaphylactic properties: A composition which comprises extracts of a plant of the genus Poncirus. The composition effectively treats allergic conditions, atopic conditions, anaphylactic conditions, and autoimmune conditions.... Agent: Charles R. De Charleroy, Jr.

20100215676 - Kdr peptides and vaccines comprising the same: The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell... Agent: Townsend And Townsend And Crew, LLP

20100215677 - Pdz domain interactions and lipid rafts: Methods for modulating immune cell signaling are provided. In general such methods involve modulating an interaction between a PDZ protein and a PDZ ligand protein whose interaction affects the composition and/or distribution of lipid rafts in an immune cell. Modulators that enhance or inhibit such interactions are also disclosed, as... Agent: Townsend And Townsend And Crew, LLP

20100215678 - Ras mutation and compositions and methods related thereto: Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations.... Agent: Sheridan Ross P.C.

20100215675 - Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza: The present invention provides methods of differentiating the infectivity and lethality of isolates of influenza virus and provides compounds for diagnosing, preventing, and treating outbreaks of influenza virus including compounds for diagnosing, preventing, and treating across different strains of influenza virus.... Agent: Kenyon & Kenyon LLP

20100215679 - Methods and compositions for treating tularemia: The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100215680 - Replikin peptides and antibodies therefor: The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease.... Agent: Kenyon & Kenyon LLP

20100215681 - Fusion proteins comprising hiv-1 tat and/or nef proteins: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or... Agent: Glaxosmithkline Corporate Intellectual Property-uw2220

20100215682 - Deletion of the beta 20-21 loop in hiv gp120 exposes the cd4 binding site for improved antibody binding and antibody induction: Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding... Agent: Klarquist Sparkman, LLP (ott-nih)

20100215683 - Protective antigens for group b streptococcus hypervirulent strains: The invention provides protective antigens for Group B streptococcus hypervirulent strains. The fragments are useful in vaccine compositions to induce protection against S. agalactiae, particularly against hypervirulent strains.... Agent: Novartis Vaccines And Diagnostics Inc.

20100215684 - Streptococcus m protein, immunogenic fragments, nucleic acids and methods of use: Isolated M proteins, or M-like proteins, of Streptococcus iniae, encoding nucleic acids, genetic constructs and antibodies which bind the isolated M proteins are provided. Also provided are isoforms and/or fragments of the M proteins, or M-like proteins, that display reduced fibrinogen binding. The isolated M proteins, antibodies and encoding nucleic... Agent: Knobbe Martens Olson & Bear LLP

20100215685 - Acyl pseudodipeptides which carry a functionalized auxiliary arm: Compounds of the present invention have immunomodulating properties like adjuvants, In addition, compounds of the invention can be grafted on a given antigen in order to modulate or tune the immune response or can be equally grafted on a pharmaceutical carrier to enhance the therapeutic effect or targeting thereof. Accordingly,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100215686 - Process for manufacturing vaccines: The present application discloses an improved method for conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100215687 - Soluble fiber combinations for weight control and improving parameters of cardiovascular health: A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including... Agent: Chalker Flores, LLP

20100215688 - Compositions for suppressing obesity: Disclosed herein is a composition for suppressing and preventing obesity and related adult diseases, comprising Herba Ephedrae and Thallus Laminariae seu Eckloniae, or comprising Herba Ephedrae, Thallus Laminariae seu Eckloniae and Radix et Rhizoma Rhei.... Agent: Dickstein Shapiro LLP

20100215689 - Soluble fiber combinations for weight control and improving parameters of cardiovascular health: A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including... Agent: Chalker Flores, LLP

20100215690 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Buchanan, Ingersoll & Rooney PC

20100215691 - Recombinant viral vectors: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.... Agent: Frommer Lawrence & Haug

20100215692 - Dengue chimeric viruses: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100215693 - Immunological herpes simplex virus antigens and methods for use thereof: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity... Agent: Karen S. Canady Canady & Lortz LLP

20100215694 - Infectious cdna of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS... Agent: Pfizer Inc Mary J Hosley

20100215695 - Hiv preventive vaccine based on hiv specific antibodies: The present invention relates to a method for producing a HIV vaccine, preventing infection with HIV and/or preventing the development of HIV infection in an individual. In particular, the present invention provides formation of HIV specific antibodies capable to recognize and bind to substantially all HIV-isoforms as an immune response... Agent: Knobbe Martens Olson & Bear LLP

20100215696 - Efficiently replicable heptitis c virus mutant, a heptitis c virus mutant comprising reporter gene, a method of preparing of hcv vaccine using the same and a method of screening anti hcv composition using the same: The present invention relates an efficiently replicating a modified hepatitis virus (HCV) mutant, and a modified HCV further comprising reporter gene, a method of preparing HCV vaccine using the same, and a method of screening anti-HCV material using the same. The present invention is to overcome the defect that the... Agent: Jhk Law

20100215698 - Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100215697 - Methods and materials for making and using vaccines: This document relates to methods and materials for making and using vaccines. For example, vaccine preparations (e.g., whole cell vaccines and cell lysate vaccines) that can be used to treat cancer (e.g., human ovarian cancer) are provided.... Agent: Fish & Richardson P.C.

20100215699 - Lactoferrin as a radioprotective agent: This present invention relates to the field of protecting against, or rectifying the effects of damaging ionizing irradiation. The method of treatment involves oral administration of a lactoferrin composition, alone or in combination with other treatments, both in combination with other radio-protective agents and/or the standard of care. Further, the... Agent: Fulbright & Jaworski, LLP

20100215703 - Composition containing vesicle-silica complex, and process for production thereof: To provide a vesicle-containing composition wherein the stability is improved and the rate of releasing drug or perfume is sufficiently restricted during administration in vivo or application to the skin surface. Silica polymerization on the outer surfaces of vesicles is facilitated by adding a specifically structured water-soluble silane derivative to... Agent: Rankin, Hill & Clark LLP

20100215701 - Cosmetic composition comprising a fine powder: The present invention relates to cosmetic compositions used in the care and make-up field. This composition mainly comprising a continuous aqueous phase, a fatty phase and a fine and porous pulverulent copolyamide powder phase, is in the form of creamy, liquid or gelled compositions. This is in particular an emulsion,... Agent: Millen, White, Zelano & Branigan, P.C.

20100215702 - Microparticles comprising pcl and uses thereof: The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric... Agent: Foley And Lardner LLP Suite 500

20100215700 - Shear gels and compositions comprising shear gels: The present invention is directed to shear gels and topical compositions comprising the same. The topical compositions can be substantially free of silicone elastomers and yield excellent sensory characteristics when applied.... Agent: Unilever Patent Group

20100215704 - Methods and products for improving wound healing: wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or pharmaceutically... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100215706 - Spinosyn fumigants: Methods of controlling arthropod pests by dispersing spinosyn compositions in the form of aerosols, fogs, smokes, or vapors are disclosed.... Agent: Dow Agrosciences LLC

20100215705 - Use of colloidal clays for sustained release of active ingredients: One aspect of the invention is a method of controlling target living species with an active ingredient over an extended period of time. This method sorbs an active ingredient into colloidal clay. Next, a polymer pellet recalcitrant to release of the active ingredient is loaded with the sorbed colloidal clay.... Agent: Mueller And Smith, Lpa Mueller-smith Building

20100215707 - Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof: Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the... Agent: Dann, Dorfman, Herrell & Skillman

20100215708 - Coating of devices with effector compounds: This invention is directed to substrates, materials and devices coated with a gel, foam, film, particle or composition comprising a polymei solvent and effector compounds attached thereto, processes of producing the same, and methods of use thereof, of in, inter-alia, biological applications, including preventing infection and the treatment of various... Agent: Pearl Cohen Zedek Latzer, LLP

20100215709 - Medical device with inflammatory response-reducing coating: Implantable non-bioabsorbable medical devices have an amphiphilic coating for reducing the inflammatory response to the device after implantation.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20100215710 - Beta-2 adrenergic receptor agonists and antagonists and modulation of wound healing: Methods for increasing rate of healing of wounds in epithelial tissues by administration of beta-2 adrenergic receptor antagonists to target patients are provided. Methods for decreasing cell growth around implanted devices and methods for decreasing wound contraction by administration of beta-2 adrenergic receptor agonists are also provided. Pharmaceutical compositions and... Agent: Townsend And Townsend And Crew, LLP

20100215712 - Blood vessel stent of amidoglucosan polysaccharide loaded with cd133 antibody and its preparation method: A blood vessel metal stent coating of amidoglucosan polysaccharide loaded with antibody comprises carrier material composed of chitosan and inartificial degradable acidic amidoglucosan polysaccharide and the effective dose of CD133 antibody loaded in the carrier material. The blood vessel metal stent coating is manufactured with self-assemble method to fix the... Agent: Squire, Sanders & Dempsey L.L.P.

20100215718 - Bone graft material containment structures: The present invention provides biocompatible, non-resorbable porous containment structures for containment of bone graft material at a desired location for stimulation of bone growth. The porous containment structures have interconnected pores sized to allow fibrovascular integration with surrounding tissue and conduction of vascular tissue through the structure into the bone... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100215716 - Compositions and methods for coating orthopedic implants: An orthopedic implant suitable for insertion into the body of a subject, the implant comprising: a metal substrate having one or more surfaces operable to contact a bone tissue or soft tissue when implanted into the subject; a coating comprising a resorbable polymer impregnated with an admixture of a rifamycin... Agent: Harness, Dickey & Pierce, P.L.C

20100215717 - Endothelial scaffolds: Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a... Agent: Myers Bigel Sibley & Sajovec

20100215715 - Gel delivery system for tissue repair: The present invention discloses methods and compositions comprising a biocompatible gel that is used in tissue repair and regeneration. Once the gel is administered to a tissue site in need of repair or regeneration, the cells migrate from the gel into the tissue and repair or regenerate the tissue.... Agent: Hogan Lovells US LLP

20100215719 - Polyarylates for drug delivery and tissue engineering: Biocompatible polyarylates of diphenol compounds and poly(alkylene oxide) dicarboxylic acids, articles formed therefrom and therapeutic uses are disclosed.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100215713 - Scaffolds for follicle transplantation: The present invention provides for a device comprising a scaffold composition, a bioactive composition and a bio-in-hibiting composition, wherein said bioactive and bio-inhibiting compositions are incorporated into or coated onto said scaffold composition, wherein said scaffold composition temporally supports survival and growth of resident follicles, migration and multiplication of stroma... Agent: Knobbe Martens Olson & Bear LLP

20100215711 - Stabilized enzyme compositions: A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material.... Agent: Baker & Hostetler LLP

20100215714 - Treatment of stroke and other acute neural degenerative disorders using postpartum-derived cells: Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.... Agent: Patton Boggs LLP

20100215720 - Implantable optical system, method for developing it and applications: The present invention refers to an implantable optical system comprising a central optical part and an annular anchoring part, where said annular part comprises animals cells, including human cells, that encourage the integration of the implant into the ocular tissue of the patient, as well as a system for dosing... Agent: Cantor Colburn, LLP

20100215721 - Poultice and process for producing the poultice: This invention provides a poultice, which can prevent both runover of a medicated layer and separation from a subject for which the poultice is applied, and a process for producing the poultice. A poultice (10) comprises a support (20) and a medicated layer (30) provided on the support (20) and... Agent: Dilworth & Barrese, LLP

20100215722 - Tissue regeneration ii: The invention relates to tissue regeneration and to therapeutic compositions, formulations and dressings.... Agent: Medlen & Carroll, LLP

20100215723 - Wound dressing with antimicrobial gauze and bonding agent: A wound dressing (500) includes a flexible layer of material (501) that is treated with an antimicrobial agent (604), such as PHMB. The antimicrobial agent (604) ionically bonds to cellulose fibers (502) of the flexible layer of material (501) through a bonding agent (601). The bonding agent (601) increases the... Agent: Philip H. Burrus, Iv

20100215726 - Compositions for diminishing the appearance of wrinkles: Topical skin care compositions are provided for the improvement of the appearance of the skin, namely of the skin comprising the face, surrounding the eyes, mouth, and hands, as well as the skin of the body. The skin care compositions include synergistic combinations of active peptide ingredients that are specially... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100215730 - Compositions for nasal administration of phenothiazines: Provided herein are pharmaceutical compositions comprising phenothiazines or derivatives thereof that are formulated for nasal administration. Also provided herein are methods of utilizing the same.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100215731 - Method for improving cartilage repair and/or preventing cartilage degeneration in a joint: The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is... Agent: Nixon & Vanderhye, PC

20100215724 - Microcapsule nanotube devices for targeted delivery of therapeutic molecules: A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical compositions and methods of treatment comprising same. The pharmaceutical compositions of the present invention enable the specific and targeted delivery of therapeutic agents such as DNA molecules,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100215729 - Oligonucleotide analogues incorporating 5-aza-cytosine therein: Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible... Agent: Wilson, Sonsini, Goodrich & Rosati

20100215725 - Pharmaceutical composition containing idebenone for the treatment of liver disorders: The invention describes the use of an injectable form of Idebenone to protect against hepatic damage, improve recovery from liver trauma, poisoning, vapor intoxication, degenerative diseases, hepatocyte function loss and pathology associated with inflammation or infection. The use of injectable Idebenone restores liver function, suppresses elevated enzyme levels, decreases alcoholic... Agent: Alpharx Inc.

20100215728 - Skincare methods: Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100215727 - Stabilized picoplatin dosage form: Methods for stabilizing aqueous solutions of picoplatin are provided. Such stable, preferably aseptic solutions are particularly useful for preparing unit dosages of picoplatin for oral or intravenous administration, preferably in combination with at least one additional non-platinum anti-cancer agent.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100215733 - Device and method for reducing calorie intake: Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach 10 and/or anywhere else in the gastrointestinal (GI) tract, absorbing or encapsulating the captured food into multiple capturing members and moving such multiple capturing members containing the ingestible encapsulated... Agent: Levine Bagade Han LLP

20100215732 - Ingestible implement for weight control: An orally administrable implement for expanding in a stomach of an animal, including a mammal, to fill a space in the stomach, is provided for weight control. The implement includes: a fluid-permeable expandable container having a first dimension and a second dimension; and a plurality of clusters comprising a swellable... Agent: Bennett Jones LLP C/o Ms Roseann Caldwell

20100215734 - Pharmaceutical compositions: The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporin or a macrolide.... Agent: Novartis Corporate Intellectual Property

20100215735 - Compounds for inhibiting beta-amyloid production and methods of identifying the compounds: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or... Agent: Bryan Cave LLP

20100215736 - Oral dosage form providing fast adsorption of drug: The invention relates to a certain oral dosage form providing absorption of the drug diclofenac in an ultrafast manner.... Agent: Novartis Consumer Health, Inc.

20100215737 - Combination pharmaceutical compositions: A modified release dosage product (5) comprises a plurality of minicapsules or minispheres (1, 2) containing nimodipine, and a plurality of minicapsules or minispheres (3), (4) containing tacrolimus. There are uncoated minicapsules or minispheres (1) encapsulating micronized nimodipine for immediate release and a controlled release polymer coated minicapsule or minisphere... Agent: Klarquist Sparkman, LLP

20100215738 - Prebiotic formulations and methods of use: The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in... Agent: Wilson, Sonsini, Goodrich & Rosati

20100215739 - Low dose topiramate / phentermine composition and methods of use thereof: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100215742 - Drug active in neuropathic pain: The present invention relates to a compound of formula (I): in which: R is a linear or branched alkyl group containing between 1 and 3 carbon atoms, Y is CH or N, and p is an integer between 0 and 3 and preferably 0 and 1, and salts thereof, either... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100215741 - Pharmaceutical compounds: e

20100215740 - Taste-masked orally disintegrating tablets of memantine hydrochloride: The present invention relates to a solid pharmaceutical composition comprising memantine, which dissolves or disintegrates in the oral cavity preferably within about 60 seconds. The present invention further discloses orally disintegrating tablets of taste-masked memantine of optimal mechanical strength comprising memantine along with a taste-masking agent and pharmaceutically acceptable excipients.... Agent: Merchant & Gould PC

20100215743 - Composition and drug delivery of bisphosphonates: The present invention provides methods of treating or preventing a medical condition that is responsive to a bisphosphonate compound in a subject. The methods comprise administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the bisphosphonate no less frequently than a bi-weekly dosage schedule. In some... Agent: Myers Bigel Sibley & Sajovec

20100215744 - Hydroxypropyl substitution used to regulate dissolution of a chemical: A method of producing a batch of a tetracycline-class component HPMC extended release pharmaceutical product having a desired dissolution profile, comprising: selecting a dissolution rate-controlling polymer comprising an HPMC component, the HPMC component having a selected % HP value; validating that the % HP in the selected HPMC component is... Agent: Ohlandt, Greeley, Ruggiero & Perle,llp Medicis Pharmaceutical Corporation

20100215745 - Compositions of spores of non pathogenic bacteria: m

20100215746 - Prevention of cisplatin induced deafness: The present invention relates to compositions and methods for the protection and restoration of hearing. In particular, the present invention relates to methods and compositions for the prevention of chemical (e.g., cisplatin) induced deafness. The present invention thus provides methods of improving the outcome of subjects treated with cisplatin.... Agent: Casimir Jones, S.c.

20100215748 - Functionalized adhesive medical gel: A bioadherent substrate includes a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20100215747 - Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers: A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP

20100215749 - Temperature- and ph-responsive polymer compositions: Temperature- and pH-responsive copolymer compositions, and drug delivery devices, conjugates, nanoparticles, and micelles that include the compositions.... Agent: Christensen O'connor Johnson Kindness PLLC

20100215753 - Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose: A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In... Agent: Davidson, Davidson & Kappel, LLC

20100215754 - Delivery system for functional compounds: A delivery system for various functional compounds is disclosed. The delivery system incorporates a composition containing alumina. Various functional materials containing particular moieties may be adsorbed onto the alumina and used as desired. The functional compounds can be, for instance, pharmaceuticals, xenobiotics, anti-microbial agents, anti-viral agents, UV absorbers, odor control... Agent: Dority & Manning, P.A.

20100215751 - Methods and compositions for treating recurrent cancer: The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.... Agent: Morrison & Foerster LLP

20100215750 - Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation: A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof... Agent: Birch Stewart Kolasch & Birch

20100215752 - Policosanol nanoparticles: The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100215755 - Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same: The present invention relates to methods of using topical or cosmetic compositions containing resveratrol ferulates for skin lightening and anti-aging applications and method of synthesizing resveratrol ferulates.... Agent: The Estee Lauder Cos, Inc

20100215756 - Pharmaceutical preparations containing highly volatile silicones: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or... Agent: Kf Ross PC

20100215758 - Effervescent nutritional and/or dietary supplement composition: An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative... Agent: Jones Day (for Nordic Naturals)

20100215757 - Envelope membrane for discharging an enclosed agent, method for the production thereof, and use thereof: The invention relates to an enveloping membrane for discharging an enclosed agent in an aqueous medium. The aqueous solution of an oxidizing chlorine-oxygen compound is enclosed is said enveloping membrane which is insoluble in a neutral aqueous medium. In an advantageous embodiment, the enveloping membrane represents a capsule structure, particularly... Agent: Fay Sharpe LLP

20100215759 - Pharmaceutical compounds: e

20100215760 - Intrinscially fluorescent carbon nanospheres and a process thereof: The present invention provides solution to the problem involved in delivery of active molecules to nucleus. More particularly, the invention provides intrinsically fluorescent and inherently surface functionalized carbon nanospheres which are non-toxic. Also, these carbon nanospheres [CSP] were adsorbed with CTPB [CSP-CTPB] and the adsorbed CSP-CTPB are permeable to cells... Agent: Fenwick & West LLP

20100215761 - Composition for regulating lipid metabolism: This invention concerns a composition for regulating lipid metabolism and methods that may be used in the food industry as well as in the nutraceutical and therapeutic fields. In particular, the invention involves food additives or supplements, a composition containing these and the use thereof, in particular for revitalizing a... Agent: Hoffmann & Baron, LLP

20100215762 - Edible composition for treating cutaneous signs of ageing: i

20100215763 - Method of using the body's alternative cellular energy pigments (ace-pigments) in the therapy of diseases: Alternative cellular energy pigments (ACE-pigments) are over-produced in response to various types of viral infections and to other pathological conditions. ACE pigments accumulate at the sites of disease and also in other regions of the body, including the oral cavity. ACE pigments are considered to play a significant role in... Agent: William John Martin

20100215765 - Antimicrobial composition and a method of controlling contamination and infection using said composition: An antimicrobial composition having the empirical formula of C10H16N6O9.... Agent: Waddey & Patterson, P.C.

20100215764 - Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts: This invention relates to a pharmaceutical composition and health food comprising herb extracts of one or more herbs selected from the group consisting of Puerariae Radix, Bombycis corpus and Araliae Continentalis Radix. The herb medicine of this invention comprising a single or mixed composition may be useful for the prevention... Agent: Sughrue Mion, PLLC

20100215766 - Use of atomic quamtum cluster (aqc) as antimicrobial agents and biocides: The invention relates to the use of stable atomic quantum clusters (AQC) with antimicrobial activity. The stable AQCs include at least 500 metal atoms (Mn, n<500), the metals being selected from among Au, Ag, Co, Cu, Pt, Fe, Cr, Pd, Ni, Rh, Pb or bi- or multi-metallic combinations thereof. Said... Agent: Merchant & Gould PC

20100215767 - Skin whitening agent: Disclosed are: a skin whitening agent including, as an active ingredient, a complex of carbonic acid and/or bicarbonic acid, a metal and an LF, a decomposition product of the complex, or a complex of carbonic acid and/or bicarbonic acid, a metal and a decomposition product of an LF; and a... Agent: Young & Thompson

20100215768 - Nutritional supplement: A nutritional supplement includes elements having been shown to enhance DNA repair or reduce DNA damage by different molecular mechanisms while excluding other bioactive nutrient agents which compete with any of the elements known modes of action. The supplement includes a resveratrol, a carotenoid, a nicotinamide, a dimethylaminoethanol, a zinc... Agent: Kelly Lowry & Kelley, LLP

20100215769 - Natural occurring nutrient supplement compositions and methods of treatment using same by improving resistance to dna damage, enhancing dna repair and stimulating immune function wherein metabolic competition is avoided: Selectively administering to humans, as a daily dosage, a combination of resveratrol-carotenoids, nicotinamide (or niacin or a precursor thereof) and a source of zinc, in excess of normal dietary levels, for improving resistance to DNA damage, enhancing DNA repair capacity, and stimulating immune function.... Agent: Stuart Garret Ronald W. Pero

20100215770 - Mixed metal compounds for treatment of hyperphosphataemia: The present invention relates to mixed metal compounds having pharmaceutical activity, especially as phosphate binders. It also extends to methods of manufacture of those compounds, as well as to pharmaceutical compositions containing such compounds. It further relates to their pharmaceutical use. In particular, the present invention relates to use of... Agent: Mayer Brown LLP

20100215772 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Inc.

20100215773 - Use of quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100215771 - Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.... Agent: Fish & Richardson PC

20100215774 - Film comprising nitroglycerin: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100215775 - Use of c10-c14-alkanediols in the preparation of a composition for the prophylaxis and/or treatment of malassezia-induced dandruff formation: The invention relates to the use of C10-C14-alkane-1,2-diols, in particular 1,2-decanediol, 1,2-dodecanediol and/or 1,2-tetradecanediol, in the preparation of a composition for the prophylaxis and/or treatment of Malassezia-induced dandruff formation, as well as to cosmetic and/or dermatological preparations comprising C10-C14-alkane-1,2-diols.... Agent: Connolly Bove Lodge & Hutz LLP

20100215776 - Method of treating a sore throat: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to... Agent: Connolly Bove Lodge & Hutz LLP

20100215777 - Malononitrile compounds: Compounds of formula (I) wherein the symbols have the meaning given in the specification, as well as processes for preparing the compounds (I), pesticidal compositions and synergistic mixtures comprising compounds (I), methods for the control of insects, acarids or nematodes by contacting the pests or their food supply, habitat or... Agent: Brinks, Hofer, Gilson & Lione

20100215779 - Compositions and methods for treating disorders associated with salt or fluid retention: Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in... Agent: Honigman Miller Schwartz & Cohn LLP/iron

20100215780 - Method for treating onychoschizia: The present invention is directed to compositions containing a combination of a herb from the genus Equisetum together with one film forming agent and its use as a nail topical formulation, like nail varnish, cream, gel, lotion or foam. The present invention is further directed to the use of a... Agent: Nixon & Vanderhye, PC

20100215778 - Method of prophylaxis: The method of human prophylaxis comprising a number of steps is claim. First, the client is prepared for a steam bath, by applying a herbal paste on the skin, over at least one area of the client's body. The herbal paste is allowed to be absorbed into the client's body... Agent: Alexey Bakman

20100215782 - Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis: Disclosed are methods, compounds, and compositions comprising botanically based drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural... Agent: Mcdermott Will & Emery

20100215781 - Therapeutic composition comprising omega-3 polyunsaturated fatty acid or derivative thereof, resveratrol and green tea: A therapeutic composition is provided comprising: (1) at least one omega-3 polyunsaturated fatty acid, at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof; (2) resveratrol or a resveratrol derivative; and (3) green tea or a green tea derivative, each in an amount, individually and in combination,... Agent: Jones Day (for Nordic Naturals)

20100215783 - Antioxidant compositions, beverage formulations thereof, and methods of increasing antioxidant capability: Compositions including synergistic combinations of ascorbic acid, Indian gooseberry, and additional components for increasing the antioxidant capability of certain target components, such as superfruits, fruits, and other low and/or high antioxidant containing substances. Particular combinations of ascorbic acid, Indian gooseberry extract, one or more citrus bioflavanoids, and one or more... Agent: Downs Rachlin Martin PLLC

20100215784 - Antimicrobial & antiviral composition: An antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares includes an antiseptic solution in combination with cocos nucifera (coconut oil) and one or more citrus oils such as, for example, citrus sinensis (orange oil). Various embodiments may also include one or more of the following... Agent: Robert M. Downey, P.A.

20100215785 - Compositions and methods for treating signs of skin aging: The invention relates to methods and compositions for treating skin aging, said compositions comprising at least one tropoelastin promoter and at least one tropoelastin crosslinker.... Agent: Philip S. Johnson Johnson & Johnson

20100215786 - Morinda citrifolia enhanced lip treatment: The present invention provides a lip treatment formulated with Morinda citrifolia juice or oil. The Morinda citrifolia lip treatment of the present invention serves to provide significant health and lip care advantages.... Agent: Kirton And Mcconkie

20100215787 - Composition for the treatment of gastrointestinal diseases: The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of gastrointestinal disease. Such compositions comprise a therapeutically effective amount of an alcohol soluble fraction derivable from potato juice.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100209340 - Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer: The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer.... Agent: Townsend And Townsend And Crew LLP

20100209341 - Treatment of chronic inflammatory conditions: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.... Agent: Foley And Lardner LLP Suite 500

20100209342 - Apcdd1 inhibitors for treating, diagnosing or detecting cancer: The invention provides, inter alia, methods for methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with APCDD1 overexpression.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100209343 - Methods and kits for diagnosis of cancer and prediction of therapeutic value: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose... Agent: Proskauer Rose LLP

20100209344 - Radio-methyl vorozole and methods for making and using the same: Radiotracer vorozole compounds for in vivo and in vitro assaying, studying and imaging cytochrome P450 aromatase enzymes in humans, animals, and tissues and methods for making and using the same are provided. [N-radio-methyl] vorozole substantially separated from an N-3 radio-methyl isomer of vorozole is provided. Separation is accomplished through use... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20100209345 - Fluorinated ligands for targeting peripheral benzodiazepine receptors: The invention provides fluorinated compounds of formula (I): The compounds may be used in diagnosis or treatment of a disorder in a mammal characterised by an abnormal density of peripheral benzodiazepine receptors.... Agent: Fenwick & West LLP

20100209346 - Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof: The invention relates to neuromodulatory oligomers of the amyloid β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers and diagnostic and therapeutic agents, for the generation of oligomer-specific antibodies and for the... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100209347 - Cyclodextrin compound modified with folic acid, process for production thereof, drug delivery agent for targeting drug delivery system, pharmaceutical composition, and imaging agent: Disclosed is a cyclodextrin compound comprising glucopyranoses constituting cyclodextrin, the glucopyranoses having substituents each having folic acid substituted for two or more primary hydroxy groups at position-6 of the glucopyranoses.... Agent: Pearne & Gordon LLP

20100209350 - Biomarkers for adipose tissue activity: The invention provides compositions and methods for determining a subject's adipose tissue activity. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, resistin, PAI-1, optionally leptin and optionally visfatin. The simultaneous use of multiple biomarkers with independent classification power... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100209351 - Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause... Agent: Mcdermott Will & Emery LLP

20100209348 - Methods for determining liposome bioequivalence: This invention provides methods for determining liposome bioequivalence between a generic drug product and a reference brand-name product. Specific methods for determining bioequivalence between doxorubicin hydrochloric acid (HCl) liposome injection product (Doxil®) and a generic pegylated liposome doxorubicin product are disclosed herein.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100209349 - Phage therapy against pseudomonas aeruginosa: This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP (Restriction fragment length polymorphism) DNA profile substantially equivalent to the bacteriophage MPK6. The present invention provides a bacteriophage MPK6 or a progeny bacteriophage thereof... Agent: Edwards Angell Palmer & Dodge LLP

20100209352 - Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and mr imaging techniques: The invention provides for methods for producing water-soluble iron oxide nanoparticles comprising encapsulating the nanoparticles in phospholipids micelles. Also provided are methods for conjugating the inventive nanoparticles via functionalized phospholipids to a target molecule, such as an antibody. The invention further provides methods for using the nanoparticle-antibody conjugate of the... Agent: Schwegman, Lundberg & Woessner/columbia University

20100209355 - Cupredoxin derived transport agents and methods of use thereof: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100209356 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula (I) and salts or optical active isomers thereof,... Agent: Ge Healthcare, Inc.

20100209354 - Organic/inorganic hybrid nanoparticulates made from iron carboxylates: The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties... Agent: Arent Fox LLP

20100209353 - Tumor targeting protein conjugate and a method for preparing the same: The present invention relates to a protein conjugate having excellent tumor targeting capacity and a method for preparing the same, more precisely albumin-bile acid conjugate forming 30-500 nm nano-particles and forming self-aggregates in water system and a method for preparing the same. The albumin-bile acid conjugate of the present invention... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100209357 - Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors: The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes... Agent: Morgan Lewis & Bockius LLP

20100209358 - Method of making particles for use in a pharmaceutical composition: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of... Agent: Davidson, Davidson & Kappel, LLC

20100209359 - Medicated chewing gum: The present invention provides a chewing gum composition comprising a chewing gum base, a biologically active ingredient, a polymeric material and one or more sweetening and flavouring agents, wherein the polymeric material is amphiphilic, has a straight or branched chain carbon-carbon backbone and a multiplicity of side chains attached to... Agent: Oliff & Berridge, PLC

20100209361 - Highly cationic copolymers based on quaternized nitrogen-containing monomers: The present invention relates to a copolymer with high cationic charge based on quaternized nitrogen-containing monomers, to cosmetic or pharmaceutical compositions which comprise at least one such copolymer, and to further uses of these copolymers.... Agent: Connolly Bove Lodge & Hutz LLP

20100209360 - Method for making a gas from an aqueous fluid, product of the method, and apparatus therefor: A method for producing a purified, stable, compressible gas from an aqueous fluid. The gas is suitable for a variety of uses and may also be infused into water which itself is useful for a variety of purposes.... Agent: Eugenia S. Hansen Hemingway & Hansen, LLP

20100209362 - Biofilm treatment: The invention provides a method of preventing, inhibiting or reducing a P. gingivalis biofilm in a subject comprising administering to the subject a pharmaceutical composition comprising an inhibiting agent of a polypeptide that reduces or inhibits biofilm formation and/or biofilm development. Also provided are compositions useful in the prevention, inhibition... Agent: Dla Piper LLP (us)

20100209364 - Emulsified composition: An emulsified composition comprises (A) petrolatum, (B) lecithin, (C) glycerin, (D) water and (E) a water-soluble polymer, wherein the content of the petrolatum (A) is 10 to 30 wt % relative to 100 wt % of the emulsified composition, and an internal phase of the emulsified composition has an average... Agent: The Webb Law Firm, P.C.

20100209367 - Emulsions of silicone elastomer and silicone organic elastomer gels: Aqueous emulsions are disclosed of a gel or gel paste containing a silicone elastomer from the reaction an organohydrogensiloxane having at least two SiH containing cyclosiloxane rings in its molecule and a compound having at least two aliphatic unsaturated groups in its molecule.... Agent: Dow Corning Corporation Co1232

20100209368 - Method and preparation for treating baldness: Various embodiments of the present invention are directed to hair-loss, and include treatments and preparations. Embodiments of the present invention include bactericides, combinations of bactericides and fungicides, combination of bactericides and vasodilators, and combinations of bactericides, fungicides, and vasodilators that are delivered topically to pilosebaceous units within the scalps of... Agent: Olympic Patent Works PLLC

20100209365 - Oil-in-water emulsion type sunscreen preparation: r

20100209363 - Personal cleansing composition including a structured surfactant system and a sun protection factor composition: A personal cleansing composition includes a structured surfactant system including a blend of surfactants that form spherulite structures in an aqueous medium. The composition also includes water, and at least one sunscreen compound. The personal cleansing composition deposits the at least one sunscreen compound onto skin in a manner whereby... Agent: The Dial Corporation

20100209366 - Uv absorbing compounds: p

20100209369 - Coloring material and its uses, in particular in the field of cosmetics, especially for making up the skin and superficial body growths: The invention relates to a solid coloring material obtained by precipitation, in an aqueous medium, of the reaction product of an alkali metal silicate with a colored complex obtained by reaction, in aqueous solution, of a hydrolysable tannin or of a plant extract comprising it with a salt of a... Agent: Woodcock Washburn LLP

20100209370 - Skin treatment composition: wherein AO is an oxyalkylene group of C3 or C4; EO is an oxyethylene group; m and n are 1≦m≦70 and 1≦n≦70 respectively, wherein EO is 20-80% by weight with respect to a total of AO and EU; each of R1 and R2 is a hydrogen or a hydrocarbon group... Agent: Andrews Kurth LLP

20100209371 - Use of resins for stabilizing colorants: A process for preparing a cosmetic composition, characterized in that it includes: optionally a pretreatment of an organic ion-exchange resin, the absorption of at least one organic colorant onto the optionally pretreated resin in order to form a resinate, the optional grinding of the resulting resinate and the incorporation of... Agent: Young & Thompson

20100209372 - Patchoulol odorant: The invention relates to the use as perfuming ingredients of 8a-alkyl-perhydro-naphthalenol derivatives, to impart odor notes of the woody-earthy type.... Agent: Winston & Strawn LLP Patent Department

20100209373 - Dithiols and use thereof for strengthening the hair: The disclosure relates to the use of dithiols for strengthening keratin materials, and to novel dithiols and to cosmetic compositions comprising them.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100209374 - Multi-phase personal care composition comprising a stabilizing perfume composition: A method of stabilizing a multiphase composition is described. The composition comprises a structured surfactant phase, a benefit phase and a perfume comprising perfume raw materials. The method comprises a step of selecting at least 70% of the perfume raw materials that have a ClogP of greater than 1.8.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100209376 - Matt wax: Cosmetic agent for temporarily shaping keratin fibers, which contains, in a cosmetically acceptable carrier, 10 to 85% by weight, based on the entire agent, of at least one wax having a melting point in the range of 40° C. to 90° C. and 1 to 15% by weight of at... Agent: Henkel Corporation

20100209377 - Hair styling and conditioning personal care films: The present invention provides personal care compositions in film form having less than about 30 weight percent water-soluble chitosan derivative and greater than about 40 weight percent of a water soluble film forming agent.... Agent: Union Carbide Chemicals And Plastics Technology Corporation

20100209375 - Process for treating keratin fibers with at least one heterocyclic disulfide entity in the presence of at least one reducing agent, optionally heat, and optionally at alkaline ph.: The present disclosure relates to a process for treating keratin fibers, comprising: applying to the keratin fibers at least one heterocyclic disulfide entity chosen from those of formula (I), optionally applying to the keratin fibers at least one reducing agent; and/or optionally heating the keratin fibers at a temperature ranging... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100209378 - Dimethylcyclohexyl derivatives as malodor neutralizers: e

20100209379 - Superabsorbent composition with tannins for odor control: The present invention also relates to a process for the preparation of a water-absorbing composition, the water-absorbing composition obtainable by this process, a composite, a process for the production of a composite, the composite obtainable by this process, chemical products, such as, for example, hygiene articles, the use of a... Agent: Smith Moore Leatherwood LLP

20100209380 - Adhesive formulations: The disclosure relates to biocompatible components useful for forming compositions for use as medical/surgical synthetic adhesives and sealants. Biocompatible components of the present disclosure may include a polymeric polyol core, which may be treated with a nitroaryl compound to form a nitro ester. The resulting nitro ester groups may be... Agent: Tyco Healthcare Group Lp

20100209381 - Copper compound-containing antifouling coating composition having improved slime resistance and storage stability: The present invention provides an antifouling coating composition, which can form an antifouling coating film capable of giving excellent slime resistance and has a property such that the recrystallization of an antifouling agent in a paint is depressed. The antifouling coating composition of the present invention is obtainable by blending... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100209382 - Polyphenol conjugates as rgd-binding compounds and methods of use: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100209383 - Use of g-csf for treating ischemia: The present invention relates to uses of granulocyte colony stimulating factor (GCSF) or fragment thereof for the preparation of a pharmaceutical composition for treating organ dysfunction caused by ischemia, whereby the pharmaceutical composition is to be administered to a patient who is subjected to a surgical or interventional procedure in... Agent: Foley And Lardner LLP Suite 500

20100209386 - Agonist and antagonist peptides of carcinoembryonic antigen (cea): The invention provides a peptide comprising an agonist of a MHC Class I binding native sequence having amino acid substitution(s) and enhanced immunogenicity compared to the native sequence. The invention also provides methods comprising the administration of the peptide.... Agent: Leydig, Voit & Mayer, Ltd.

20100209387 - Enhanced medical implant: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth... Agent: Taft, Stettinius & Hollister LLP

20100209384 - Sustained release formulations comprising very low molecular weight polymers: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.... Agent: Hunton & Williams LLP Intellectual Property Department

20100209385 - Treatment of obesity: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via... Agent: Knobbe Martens Olson & Bear LLP

20100209390 - Cyclosporin analogues: e

20100209389 - Multi-compartmented container: The invention provides a multi-compartmented container suitable for the delivery of pharmaceuticals, medicines, vitamins, and the like.... Agent: Pfizer Inc. Patent Department

20100209388 - Nutraceutical composition and method of use for treatment / prevention of cancer: The invention describes a nutraceutical composition and method for preventing/treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, B3, C and pantothenate C) lactic... Agent: Elizabeth Mazzio Florida A & M University

20100209391 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in... Agent: Knobbe Martens Olson & Bear LLP

20100209392 - Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination... Agent: Robins & Pasternak

20100209393 - Use of polynucleotides encoding small acid-soluble spore protein for inhibiting bacterial cell growth and/or treating bacterial infections: A polypeptide having α/β type SASP activity, for use as a medicament.... Agent: Crowell & Moring LLP Intellectual Property Group

20100209394 - Mitogen activated protein kinase modulator: The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.... Agent: Darby & Darby P.C.

20100209406 - Bacillus strains and methods for reducing e. coli disease and enhancing performance: Bacillus strains that inhibit pathogenic swine E. coli and/or improve performance are provided. Inhibition of pathogenic swine E. coli decreases E. coli disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred Bacillus strains are of species that are included on... Agent: Whyte Hirschboeck Dudek S.c. Intellectual Property Department

20100209410 - Combinations comprising a fungicidal strain and an active compound: c

20100209407 - Mc-1r, mc-2r, and/or mu opioid receptors modulation: The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the μ opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain... Agent: Basf Beauty Care Solutions France

20100209395 - Solenopsis invicta virus: A Unique Solenopsis invicta virus (SINV 3) has been identified and its genome sequenced. Oligonucleotide primers have been developed using the isolated nucleic acid sequences of the SINV 3. The virus is used as a biocontrol agent for control of fire ants.... Agent: Usda, Ars, Ott

20100209403 - Adherent cells from adipose or placenta tissues and use thereof in therapy: A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100209402 - Agent for promoting corneal endothelial cell adhesion: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial... Agent: Leydig Voit & Mayer, Ltd

20100209399 - Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects: The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system,... Agent: Karen S. Canady Canady & Lortz LLP

20100209398 - Compositions of stem cells and stem cell factors and methods for their use and manufacture: Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability... Agent: Stemedica Cell Technologies, Inc

20100209404 - Enhanced method for producing stem-like cells from somatic cells: The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from low passage somatic cells, e.g., fibroblasts.... Agent: Edwards Angell Palmer & Dodge LLP

20100209397 - Method for non-autologous cartilage regeneration: The present invention relates in general to the field of tissue engineering, and in particular to methods for repair and regeneration of diseased and injured bone and cartilage tissue by allotransplantation or xenotransplantation of neonatal mandibular condyle-derived chondrocytes. The composition may comprise mandibular condyle-derived chondrocytes in the form of a... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100209396 - Method of enhancing proliferation and/or hematopoietic differentiation of stem cells: The present invention provides methods for inducing differentiation of a stem cell, such as an embryonic stem cell, into a hematopoietic stem cell, by expressing a cdx gene and/or a hox gene. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell... Agent: David S. Resnick

20100209405 - Sericin extracted silkworm fibroin fibers: The present invention provides a novel silk-fiber-based matrix having a wire-rope geometry for use in producing a ligament or tendon, particularly an anterior cruciate ligament, ex vivo for implantation into a recipient in need thereof. The invention further provides the novel silk-fiber-based matrix which is seeded with pluripotent cells that... Agent: Allergan, Inc.

20100209400 - Tak1-mediated regulation of osteogenesis: This invention is directed to methods, nucleic acids and compositions in TAK1-mediated regulation of SMAD activity. Promotion of TAK1 interaction with MH2 domains in SMADs negatively regulates SMAD biological activity. BMP-mediated SMAD activity is subject to TAK1 effects.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100209401 - Use of sdf-1 to improve ischemic myocardial function: A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1).... Agent: Cooper & Dunham, LLP

20100209409 - Method for suppressing immune system response to transplanted tissue or cells: Methods are provided for suppressing the immune system response in recipients of transplanted organs, tissues or cells. An extracorporeal quantity of blood from the intended transplant recipient is treated to induce monocytes contained in the blood to differentiate and form dendritic cells. The maturation of the dendritic cells is truncated... Agent: Mccarter & English, LLP Hartford Cityplace I

20100209408 - Remodeling of tissues and organs: The invention provides methods of repairing damage to, or defects in, mammalian tissues or organs. In these methods, a particulate or non-particulate acellular matrix made from a tissue or organ other than the tissue or organ being repaired is placed in or on the organ or tissue that is being... Agent: Finnegan/kci

20100209411 - Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears: A composition for removal of biofilm in the ears is useful for the treatment of ear infections such as otitis media, particularly those infections caused by Pseudomonas aeruginosa. In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects... Agent: Lewis Kohn & Fitzwilliam LLP

20100209412 - Osteogenesis promoter: It is intended to provide an osteogenesis promoter capable of promoting osteogenesis by promoting the differentiation of osteoblasts, and foods, drinks, drugs or feeds for promoting osteogenesis. Namely, an osteogenesis promoter capable of promoting osteogenesis by promoting the differentiation of osteoblasts which comprises, as the active ingredient, lactoperoxidase and/or a... Agent: Young & Thompson

20100209413 - Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death: Methods, oligonucleotides arrays etc. for treating inflammatory conditions and of predicting subject outcome based on polymorphisms in SERPINE1 and/or PROC, alone or in combination, wherein the method of treatment includes administering to the subject an anti-inflammatory agent or an anti-coagulant agent, wherein said subject is determined to have an improved... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100209415 - Chemotherapeutic methods and compositions: Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.... Agent: Bozicevic, Field & Francis LLP

20100209416 - Immunoassays for lamotrigine: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also,... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100209414 - Methods and compositions related to cyclic peptide synthesis: Disclosed are compositions and methods for prenylation of polymers such as peptides.... Agent: Ballard Spahr LLP

20100209422 - Antibodies specific for the protofibril form of beta-amyloid protein: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human β-amyloid peptide as compare to low molecular weight forms of β-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100209417 - Antibody treatment of alzheimer's and related diseases: Provided is an antibody that selectively binds to an epitope formed by residues 1-11 of Aβ in an Aβ oligomer, a method comprising using the antibody to treat a disease characterized by such an Aβ amyloid deposit in a patient, and kits comprising same.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20100209419 - Method and formulation for treating adverse biological conditions: o

20100209423 - Methods of inhibiting the binding of p-selectin to psgl-1: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100209420 - Methods of treating cancer using pyridopyrimidinone inhibitors of p13k alpha: i

20100209418 - Solid forms of a raf kinase inhibitor: The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the same.... Agent: Novartis Corporate Intellectual Property

20100209421 - Targeting pax2 for the treatment of breast cancer: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the certain embodiments, the method of inhibiting expression of PAX2 is to administrate the subject a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in... Agent: Morris Manning Martin LLP

20100209424 - Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof: In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.... Agent: David S. Resnick

20100209425 - Blood-brain barrier targeting anti-bodies: This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention... Agent: Quarles & Brady LLP

20100209428 - Antibody targeting osteoclast-related protein siglec-15: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of... Agent: Dorsey & Whitney LLP Intellectual Property Department

20100209426 - Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/tcf-mediated transcriptional pathway is con: The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active.... Agent: Young & Thompson

20100209427 - Lysine acetylation sites: The invention discloses 1302 novel acetylation sites peptides (including AQUA peptides) comprising an acetylation site of the invention, antibodies specifically bind to a novel acetylation site of the invention, and diagnostic and therapeutic uses of the above. The acetylation sites identified provide important information regarding metabolism in energy signaling pathways.... Agent: Nancy Chiu Wilker, Ph.d. Chief Intellectual Property Counsel

20100209430 - Method for treating erectile dysfunction: A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile... Agent: Kaplan Gilman & Pergament LLP

20100209429 - Peptides and methods for the treatment of gliomas and other cancers: The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrPC. The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrPC interaction and to... Agent: White & Case LLP Patent Department

20100209431 - Metal triangulo compound and methods of using the same: The present invention relates to a metal triangulo compound. Provided is also a method of inducing apoptosis in a cell that comprises administering the metal triangulo compound. Provided is also a method of preventing carcinogenesis in a cell that comprises administering the metal triangulo compound.... Agent: Foley & Lardner LLP

20100209432 - Monoclonal antibodies against glypican-3: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20100209434 - Antibody formulation: The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide.... Agent: Medimmune, LLC Patrick Scott Alban

20100209435 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100209433 - Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists: n

20100209436 - Method for treating diseases related to mitochondrial dysfunction: The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered... Agent: Foley And Lardner LLP Suite 500

20100209437 - Anti-cd3 antibody fromulations: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100209439 - Anti-prominin-1 antibody having adcc activity or cdc activity: To achieve a solution to the above-mentioned objective, the present inventors produced recombinant antibodies by cloning a nucleotide sequence of the AC133 antibody variable region, discovered that the ADCC/CDC-inducing effect which does not exist in the original AC133 antibody is imparted to the recombinant antibodies, and thereby completed the present... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100209438 - Ovr110 antibody compositions and methods of use: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another... Agent: Licata & Tyrrell P.C.

20100209441 - Drug for suppressing pathogen occurring in vivo: The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100209440 - Targeted delivery of sirna: The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the... Agent: David S. Resnick

20100209442 - Deglycosylated and desialidated long pentraxin ptx3: Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and... Agent: Lucas & Mercanti, LLP

20100209444 - Mage3 polypeptides: The present invention relates to novel MAGE3 polypeptides, including a fragment of MAGE3 fused to an immunological fusion partner, and compositions thereof.... Agent: Glaxosmithkline Corporate Intellectual Property

20100209445 - Mutant double cyclized receptor peptides inhibiting beta1-adrenoceptor antibodies: The present invention relates to novel β-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule... Agent: Stephen M Haracz Bryan Cave LLP

20100209443 - Vaccine for the prevention of breast cancer relapse: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective... Agent: Latimer Intellectual Property Law, LLP

20100209446 - Ostertagia vaccine: The present invention relates to nucleic acid sequences encoding a 30 kD Brachyspira hyodysenteriae lipoprotein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such lipoproteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or... Agent: Intervet/schering-plough Animal Health

20100209447 - Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to... Agent: Lawson & Weitzen, LLP

20100209448 - Synthetic anti-candida albicans oligosaccharide based vaccines: The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenic Candida species.... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100209449 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of... Agent: Jones Day

20100209450 - Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100209451 - Compositions and methods related to adenovirus based delivery of antigens: Embodiments of the present invention include the construction and generation of a multi-use adenoviral vaccine platform applicable to biodefense, and emerging and re-emerging infectious diseases. Adenoviral vaccines of the invention will elicit an immune response against pathogenic organisms that cause such infectious diseases. In certain aspects of the invention, the... Agent: Fulbright & Jaworski L.L.P.

20100209453 - Circovirus sequence associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-strucutral polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Buchanan, Ingersoll & Rooney PC

20100209452 - Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof: The present invention provides compositions comprising an antigen, an amphipathic compound, and a hydrophobic carrier and methods of using these compositions for inducing an antibody or cell-mediated response in a subject.... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100209454 - Attenuated viruses useful for vaccines: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in... Agent: Kenyon & Kenyon LLP

20100209455 - Thermal inactivation of rotavirus: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20100209456 - Treating neoplasms with neurotoxin: The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to... Agent: Frommer Lawrence & Haug

20100209457 - Pneumococcal serotype 6d: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→4) ribitol (5→phosphate. This new serotype may be included in... Agent: Nixon Peabody, LLP

20100209459 - Alkaloid formulations: There is provided an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents.... Agent: Michael Best & Friedrich LLP

20100209458 - Amphiphilic molecule, molecular assembly comprising the amphiphilic molecule, and use of the molecular assembly: The present invention provides an amphiphilic molecule having a plurality of zwitterionic functional groups in its hydrophilic moiety and a molecular assembly comprising the amphiphilic molecule as a constituent lipid. According to a preferred embodiment of the present invention, the molecular assembly of the present invention forms a stable vesicular... Agent: Darby & Darby P.C.

20100209460 - Anti-odor agent having disinfecting or bactericidal effect: A liquid-based anti-odor agent is provided that has a disinfectant or bactericidal effect for the interiors of shoes and for shoe parts, particularly for shoe insoles, characterized in that the anti-odor agent comprises copper or copper compounds.... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20100209461 - Purified component of blue-green algae and method of use: Disclosed herein are extracts of blue green algae, such as Aphanizomenon flos aquae, that are enriched for a selectin ligand, such as an L-selectin ligand. Selectin ligands isolated from blue-green algae cells are disclosed herein. Methods are described for isolating these selectin ligands. The purified selectin ligands are of use... Agent: Klarquist Sparkman, LLP

20100209464 - Color cosmetic: A foundation having a shade which covers a wide spectrum of different skin tones and undertones, comprises red and gold interference pigments, which provide a formula that is adaptable to both red and yellow skin undertones. The composition virtually eliminates the risk of application of the wrong foundation color, and... Agent: Cislo & Thomas LLP

20100209462 - Cosmetic compositions comprising esters based on 2-propylheptanoic acid: The invention relates to esters of 2-propylheptanoic acid and also to the use of esters of 2-propylheptanoic acid in cosmetic and/or pharmaceutical preparations. The compounds are characterized by the particularly lightweight sensation thereof.... Agent: Fox Rothschild LLP

20100209466 - Merocyanine derivatives: e

20100209465 - Shaving compositions comprising dye-loaded particles:

20100209463 - Uv filter capsule: The present invention relates to UV filter capsules, to the use thereof for the preparation of cosmetic or dermatological formulations or dispersions, and to cosmetic or dermatological formulations which comprise the capsules, and to a process for the production thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20100209468 - Implantable devices for producing insulin: The present invention generally relates to implantable devices for producing insulin in diabetic animals. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and/or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent... Agent: Joseph J. Crimaldi Roetzel & Andress

20100209467 - Tdf-related compounds and analogs thereof, analogs and bioactive fragments: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100209469 - Controlled release of nitric oxide and drugs from functionalized macromers and oligomers: The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as... Agent: Raymond R. Moser Jr., Esq. MoserIPLaw Group

20100209470 - Demineralized bone matrix devices: The invention relates to a sheet-form demineralized bone matrix (DBM) composition comprising an aqueous admixture of DBM particles, starch and gelatin, wherein the DBM particles are present in an amount of between about 30% and about 70% by weight, the gelatin is present in an amount between about 10 and... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100209472 - Drug releasing coatings for medical devices: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100209473 - Intraluminal device with a coating containing a therapeutic agent: The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device, provided with at least one coating containing a therapeutic agent comprised in a matrix which sticks to the intraluminal device, characterised in that said matrix is formed by a biocompatible oil... Agent: Clark & Elbing LLP

20100209474 - Malleable implants containing demineralized bone matrix: Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising a polysaccharide. Also described are methods for making and using such medical compositions.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100209471 - Medical devices having polymeric nanoporous coatings for controlled therapeutic agent delivery and a nonpolymeric macroporous protective layer: An implantable or insertable medical device is provided which contains the following: (a) a substrate, (b) a therapeutic agent-containable region disposed over the substrate, (c) a nanoporous polymeric layer disposed over the therapeutic agent-containable region and (d) a macroporous non-polymeric layer disposed over the nanoporous polymeric layer. The nanoporous polymeric... Agent: Mayer & Williams PC

20100209476 - Coating comprising a terpolymer comprising caprolactone and glycolide: The present invention provides a coating comprising a reservoir layer comprising a terpolymer comprising caprolactone and glycolide and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20100209475 - Medical implants having a drug delivery coating: Medical implants having a drug delivery coating, comprising a diffusion matrix made of a collagen matrix, a bioactive material, and a self-arranging transport barrier layer. The bioactive material is contained in the collagen matrix layer and/or the self-arranging transport barrier layer. Methods of preparing the coated implants and methods of... Agent: Harness, Dickey & Pierce, P.L.C

20100209478 - Drug delivery through hydrogel plugs: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel... Agent: Dardi & Herbert, PLLC

20100209477 - Sustained release delivery of one or more agents: The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100209479 - Compositions and methods for treating cancer: The present invention relates to compositions and methods for treating cancer and, in particular, to composition and methods comprising nanostructures. In one embodiment, the present invention provides a composition comprising a mixture, the mixture comprising at least one nanoparticle and at least one chemotherapeutic.... Agent: Kilpatrick Stockton LLP

20100209480 - Galenical formulations of organic compounds: wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes... Agent: Novartis Corporate Intellectual Property

20100209482 - Dressing securing system: A dressing securing system for securing a dressing relative to a wound, the dressing securing system comprising a fabric composed of a resilient knitted material.... Agent: Nixon Peabody LLP

20100209481 - New wound dressing compositions: A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.... Agent: Morgan, Lewis & Bockius LLP

20100209483 - Transdermal delivery of meptazinol: A delivery system for the delivery of a salt of meptazinol which increases the bioavailability of meptanizol by an effective amount to provide analgesic relief is disclosed. One embodiment of the delivery system is a transdermal device which increases the skin flux of meptazinol by an effective amount to provide... Agent: Frommer Lawrence & Haug

20100209484 - Transdermal triptan delivery system: This invention relates to transdermal system for the systemic administration of an active ingredient such as a triptan selected from the group comprising eletriptan, frovatriptan, sumatriptan, zolmitriptan, naratriptan, rizatriptan and almotriptan uniformly over periods of 12 to 24 hours or more thereby reducing the probability of recurring migraine. The formulation... Agent: Gibbons P.C.

20100209489 - Formulations of desvenlafaxine: Controlled release formulations of active compounds with pH-dependent solubility are provided. The formulations comprise solubility modulators which minimize the influence of environment on the solubility of the active compounds.... Agent: Foley And Lardner LLP Suite 500

20100209493 - Hla-a2 tumor associated antigen peptides and compositions: A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100209490 - Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor: The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100209494 - Liposomes and uses thereof: The invention relates to the field of molecular medicine and pharmacology. More specifically, it relates to liposomes and their use as delivery vehicle for therapeutic compounds. Provided is a liposome comprising at least one lipid bilayer enclosing an interior compartment, wherein said lipid bilayer comprises at least one synthetic pyridinium-derived... Agent: Banner & Witcoff, Ltd.

20100209491 - Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv: A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.... Agent: Sughrue Mion, PLLC

20100209486 - Method of enhancing coenzymeq10 levels in mammals: The invention relates to a method of enriching the CoEnzyme Q10 levels in mammals through supplementing CoQ9 or the compositions containing CoQ9. The present invention further relates a therapeutic method for obtaining potent antioxidant, cardioprotective, immunomodulating anticancer effects similar to those obtained with CoQ10 supplementation, by enhancing the CoQ10 levels... Agent: Kramer & Amado, P.C.

20100209487 - Nicked or gapped nucleic acid molecules and uses thereof: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary... Agent: Schwabe, Williamson & Wyatt, P.C.

20100209488 - Protein kinase modulating compounds and methods for making and using them: The invention provides compositions, e.g., small molecules, that disrupt the activity of protein kinases, including constitutively activated protein kinases, such as kinases constitutively activated through mutations, and kinases in their native inactivated state, and methods for making and using them. In one aspect, compositions of the invention bind a protein... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100209485 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.... Agent: Dla Piper LLP (us)

20100209492 - Targeted liposomal drug delivery system: A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100209495 - Granulates, process for preparing them and pharmaceutical products containing them: A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule... Agent: Buchanan, Ingersoll & Rooney PC

20100209496 - Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide: 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one (Compound I) has surprisingly improved solubility, bioavailability and stability in an ampiphilic vehicle that can include propylene glycol, a propylene glycol sparing agent, an antioxidant, or a mixture thereof. In one embodiment of the present invention is a solution comprising the active or a pharmaceutically acceptable salt or solvate... Agent: Merck

20100209497 - Formulations for treating human and animal diseases: The present disclosure provides for a scientific formulation useful in the treatment and prevention of human and animal diseases. A biologically effective amount of each of the components of the formulation is administered to patients in pill (or capsule) form via multiple different and identifiable pills. The compounds of the... Agent: Lanier Ford Shaver & Payne P.C.

20100209498 - Pharmaceutical compositions of duloxetine: The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100209499 - Solid oral dosage form containing an enhancer: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty... Agent: Myers Bigel Sibley & Sajovec

20100209500 - Controlled release budesonide minitablets: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, an extended release polymer, and an acid. The budesonide may be embedded in the extended release polymer to facilitate extended release... Agent: Dinsmore & Shohl LLP

20100209501 - Controlled release budesonide minitablets: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, and an extended release polymer. The budesonide may be embedded in the extended release polymer to facilitate extended release of the... Agent: Dinsmore & Shohl LLP

20100209502 - Treatments which alleviate functional glycosylated leptin transport factor for controlling weight and obesity: Methods and compounds for treating obesity and inducing weight loss use a functional, glycosylated leptin transport factor (LTF) polypeptide, referred to as fn/glyLTF. An unstable defective version of the LTF protein, referred to herein as def/LTF, is present in freshly-drawn blood from obese animals or people; it is degraded rapidly... Agent: Senniger Powers LLP

20100209503 - Bitter taste masking dosage form: A powder•particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100209504 - Process for production of crystalline cellulose and tablets containing granules: A process for producing a granule-containing tablet comprising mixing more than 25 mass % to 89 mass % or less of crystalline cellulose exhibiting a tensile displacement at break of 25 to 80 μm and a relative fluidity index of 2.15 to 2.80 at a maximum compaction stress of 15... Agent: Greenblum & Bernstein, P.L.C

20100209505 - Controlled release pharmaceutical formulations of nitazoxanide: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue... Agent: Foley And Lardner LLP Suite 500

20100209507 - Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune... Agent: Davis Wright Tremaine LLP/los Angeles

20100209506 - Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof: The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100209508 - Substituted phenylphosphates as mutual prodrugs of steroids and ß-agonists for the treatment of title pulmonary inflammation and bronchoconstriction: A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between 5.0 and... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100209509 - Bifunctional-modified hydrogels: Disclosed are hydrogels wherein a polymer matrix is modified to contain a bifunctional poly(alkylene glycol) molecule covalently bonded to the polymer matrix. The hydrogels can be cross-linked using, for example, glutaraldehyde. The hydrogels may also be crosslinked via an interpenetrating network of a photopolymerizable acrylates. The hydrogels may also be... Agent: Michael Best & Friedrich LLP

20100209511 - sustained release pharmaceutical formulation: A sustained release pharmaceutical formulation is disclosed. The formulation comprises a water soluble medicament and a polymer mixture comprising a first component of about 80 weight percent polyvinylacetate combined with about 20 weight percent polyvinyl pyrrolidone; of the total weight of the first component, combined with a second component of... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100209510 - Extended release formulation and method of treating adrenergic dysregulation: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of... Agent: Myers Bigel Sibley & Sajovec

20100209512 - Particle size-structured parenteral dispersions: A Drug/Adjuvant Delivery System (D/A DS), and associated method, are disclosed. An exemplary D/A DS system includes a liquid carrier; and a particle-size structured dispersion of solid and/or liquid particles suspended in the liquid carrier.... Agent: Buchanan, Ingersoll & Rooney PC

20100209513 - Pharmaceutical composition containing micronized particles of naphthoquinone-based compound: Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound.... Agent: Birch Stewart Kolasch & Birch

20100209517 - Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same: (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or pure (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of proprionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives and oxicams.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100209515 - Electricity-generating particulates and the use thereof: The invention features a galvanic particulate including a first conductive material and a second conductive material, wherein both the first conductive material and the second conductive material are exposed on the surface of the particulate, wherein the particle size of the particulate is from about 10 nanometers to about 100... Agent: Philip S. Johnson Johnson & Johnson

20100209514 - Method of treating pain by administering 24 hour oral oploid formulations exhibiting rapid rate of initial rise of plasma drug level: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause... Agent: Mcdermott Will & Emery LLP

20100209516 - Triggered drug release via physiologically responsive polymers: A drug delivery system, product and method which effectuates delivery of appropriate amounts of a pharmaceutically active agent only upon stimulus of a physiological agent released during a disease event are described. A polymer that can bind to a specific biological stimulus and respond with a specific response is included.... Agent: The Johns Hopkins Universityapplied Physics Labora Office Of Patent Counsel

20100209518 - Micro-particles, blood-substitute and method for forming same: A method for forming micro-particles is provided. The method includes the steps of: —providing a first solution which includes at least an anion; —providing a second solution which includes at least a cation; —mixing the first solution with the second solution in presence of at least a first compound for... Agent: Leon R. Yankwich

20100209519 - Pharmaceutical composition for inhalation delivery and fabrication method thereof: A pharmaceutical composition for inhalation delivery is provided, including drugs and a gelatin nanoparticle encapsulating the drugs to form a drug-gelatin nanocomplex, wherein the surface of the gelatin nanoparticle is modified with cell-targeting molecules. A method for fabricating the pharmaceutical composition for inhalation delivery is also provided.... Agent: Quintero Law Office, PC

20100209520 - Oral pharmaceutical preparation for colon-specific delivery: The present invention relates to an oral pharmaceutical preparation having an excellent capability of delivering a drug to colon, more specifically an oral pharmaceutical preparation for delivering a drug to colon and comprising a core comprising at least a pharmaceutically acceptable vehicle, an inner layer covering said core and comprising... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100209522 - Embolization: Embolization, as well as related particles, compositions, and methods, are disclosed.... Agent: Fish & Richardson PC

20100209521 - Sensory pigmets used on food, packaging, paper and pharmaceutical and electronic products: The invention relates to sensory pigments for use in foods, packagings, pharmaceutical products, paper and electronic products. Said pigments are characterised by the fact that a chemically reactive polymer layer that is 5 to 500 nm thick is applied to metallic particles, metal particles or particles containing at least one... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100209524 - Encapsulated agglomeration of microcapsules and method for the preparation thereof: Microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary... Agent: Mckeon Meunier Carlin & Curfman LLC

20100209523 - Powder composition: A powder composition, includes: (A) an oil-soluble antioxidant substance powder; (B) a water-soluble antioxidant substance powder; and (C) at least one of zinc, selenium, manganese and copper.... Agent: Sughrue-265550

20100209525 - Methods for preparing polymer microparticles: The present invention describes methods and tools for preparing a population of monodisperse polymer microparticles, which are of particular interest in the field of drug delivery.... Agent: Philips Intellectual Property & Standards

20100209526 - Product comprising a combination of milk serum apoproteins and free fatty acids: The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a... Agent: Technology Law, PLLC

20100209527 - Composition for prevention or treatment of disease associated with production of autoantibody: e

20100209529 - Pharmacologic-functioning water and usage of the same: The present invention provides a new pharmacologic-functioning water demonstrating pharmacologic function without any side effects, and usage of the same. The pharmacologic-functioning water, which demonstrates pharmacologic function without any side effects and includes antioxidant-functioning water as an active principle containing hydrogen-dissolved water, which is made up of molecular hydrogen used... Agent: Greenblum & Bernstein, P.L.C

20100209528 - Storage-stable aqueous solutions of chlorine dioxide and methods for preparing and using them: The present invention is for extremely pure solutions of chlorine dioxide, methods for making such solutions and to compositions and methods for storing, shipping and using such solutions. Generally, the chlorine dioxide solutions of the invention are aqueous solutions containing about 2500 ppm or less of total impurities. The chlorine... Agent: Ratnerprestia

20100209530 - Anti-allergen agent: The present invention provides an anti-allergen agent that has excellent heat resistance, low coloration, excellent processability, and excellent water resistance, an anti-allergen product, and a method for processing same. The anti-allergen agent of the present invention comprises as an active ingredient an inorganic solid acid, and the inorganic solid acid... Agent: Birch Stewart Kolasch & Birch

20100209531 - Oxides for wound healing and body repair: The invention provides a homogeneous composition comprising a hemostatically effective amount of a charged oxide, wherein the composition has an isoelectric point, as measured in calcium chloride, below 7.3 or above 7.4. Typically, the charged oxide is selected from the group consisting of silaceous oxides, titanium oxides, aluminum oxides, calcium... Agent: Bozicevic, Field & Francis LLP

20100209532 - Targeted oxygen delivery via intravenous or intra-arterial infusion of oxygenated polymerized hemoglobin solutions: A method of delivering oxygen to a tissue, a blood vessel, an organ, or a region of an organ, under an ischemic condition, or prophylactically preventing occurrence of an ischemic condition, of a subject, comprising the step of administering to the subject an oxygenated hemoglobin solution, wherein the oxygenated hemoglobin... Agent: Jones Day

20100209533 - Chemical composition for use as a disinfectant: A chemical composition is disclosed for a disinfectant, which is particularly usefully for disinfecting toothbrushes and other oral and/or dental products. One or more chemical compositions may be applied to an object, such as the bristles of a toothbrush with a portable spray container.... Agent: Walter J. Tencza Jr.

20100209534 - Method of treating viral conditions: An antiviral composition and a method of treating viral conditions comprising colloidal silver and an antiviral natural herb or a natural herb from the Rutaceae family, such as Ruta graveolens, Myrtaceae family, such as Melaleuca alternifolia, Cupressaceae family, such as Thuja occidentalis, and the Moraceae family, such as unripe fig,... Agent: Cislo & Thomas LLP

20100209535 - Method of treating viral conditions: An antiviral composition and a method of treating viral conditions comprising colloidal silver, silver nitrate, or both, and an antiviral natural herb or a natural herb from the Rutaceae family, such as Ruta graveolens, Myrtaceae family, such as Melaleuca alternifolia, Cupressaceae family, such as Thuja occidentalis, and the Moraceae family,... Agent: Cislo & Thomas LLP

20100209536 - Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases: This invention provides methods of treating and preventing diseases or conditions of the immune system or infectious disease, involving administration of vitamin D and/or one or more antioxidants (e.g., vitamin E and/or zinc).... Agent: Clark & Elbing LLP

20100209537 - Metal complexes with anticancer activity: The present invention relates to new substituted Quinoxaline compounds, their tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs, to the pharmaceutically acceptable salts of the compounds, tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs, to compositions of any of the aforementioned embodiments together with pharmaceutically acceptable carriers, and to uses of any... Agent: Ramesh Bangalore

20100209538 - Ph-modulated formulations for pulmonary delivery: An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts... Agent: Bozicevic, Field & Francis LLP

20100209539 - Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye: The present invention relates to compositions comprising at least one flavonoid for the treatment or amelioration of a disease or disorder of the eye and/or the adnexa of the eye in an animal subject, including a human being. More particularly, this invention relates to a composition for the treatment of... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20100209540 - Inhalation formulation for treating and prophylactic use in bacteria, mycobacterial and fungal respiratory infections: A composition for the treatment and prophylactic management of bacterial and fungal respiratory infections is provided. The composition may contain a combination of a quaternary ammonium compound and hypertonic saline to be administered to a patient in need thereof.... Agent: Townsend And Townsend And Crew, LLP

20100209541 - Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent: Cooley LLP Attn: Patent Group

20100209543 - Compositions and methods of use: This invention relates to the use of plant extracts, compositions thereof, and compounds isolated from plant extracts or obtained from synthetic means thereof, for the treatment of diseases, disorders or symptoms thereof (e.g., proliferation disorders, cancer).... Agent: Edwards Angell Palmer & Dodge LLP

20100209542 - Methods for treating withdrawal from addictive compounds: Kratom (Mitragynia speciosa korth) is recognized increasingly as a remedy for opioid withdrawal by individuals who self-treat chronic pain and/or generalized substance abuse. For example, opioid withdrawal from an abrupt cessation of opiate abuse may be self-managed by using Kratom. Further, high-throughput molecular screening identified that a major component of... Agent: Peter G. Carroll Medlen & Carroll, LLP

20100209544 - Botanical extracts from oil palm vegetation liquor for cosmeceutical applications: A cosmeceutical composition comprising phenolic compounds, fruit acids and sugars. extracted from the vegetation liquor of the palm oil milling process has been suggested. This composition is rich in antioxidants, and significantly improves skin health, including preventing aging of the skin.... Agent: Foley & Lardner LLP

20100202962 - Cripto blocking antibodies and uses thereof: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20100202961 - D-amino acid peptides: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)-R3(Y)-NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond... Agent: Immunomedics, Inc.

20100202963 - Therapies for hematologic malignancies: e

20100202964 - Organ homing genes of cancer metastases: Provided herein are methods that use liver targeting domains of colon cancer, such as for example PA28alpha, HNRNPA1, and/or KIAA1407, and the polynucleotides that encode them, for the prognosis, diagnosis, detection, staging and/or prediction of survival rates in individuals with colon cancer, whether the cancer has metastasized or not, as... Agent: Wolf Greenfield & Sacks, P.C.

20100202965 - Annulus fibrosus detection in intervertebral discs using molecular imaging agents: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N′,N″,N′″-tetraacetic acid)... Agent: General Electric Company Global Research

20100202971 - Compound having tumor-resident property: wherein R is an anionic group binding to hydrogen, R1 is OH, OCOH, OCO(CH2)hCH3, or an acting group, h being an integer of 0 or more, R2 is H, OH, OCOH, OCO(CH2)iCH3, or an acting group, i being an integer of 0 or more, R3 is OH, SO3H, or an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100202967 - Fibrin binding pepetide conjugates for diagnostic and therapeutic applications: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel peptides able to bind fibrin, to a process for their preparation and to compositions thereof for use in therapy and diagnostics. The compounds of the invention bind, in particular, to fibrin present in the... Agent: Lucas & Mercanti, LLP

20100202966 - Implantable sensor: Apparatus is provided for detecting a concentration of an analyte in a subject. The apparatus includes a housing (20) adapted to be implanted in the subject. The housing (20) comprising an optical detector (30) adapted to detect a level of fluorescence resonance energy transfer (FRET). The apparatus also comprises live... Agent: Cooper & Dunham, LLP

20100202970 - Intracellular reporters: The invention provides a variety of molecular tools for use in live-cell tracking of activities of biomolecules and in high-throughput drug screening.... Agent: Banner & Witcoff, Ltd.

20100202968 - Method of providing disease-specific binding molecules and targets: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20100202969 - Nanoparticles for imaging and treating chlamydial infection: Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against Chlamydia.... Agent: C. Rachal Winger C/o Ocip Group

20100202973 - Microrna molecules associated with inflammatory skin disorders: This invention relates to the finding that inflammatory skin disorders, such as psoriasis and atopic eczema, are characterized by changes in the expression of specific microRNA molecules (miRNAs). These miRNAs may therefore be useful as biomarkers for inflammatory skin disorders as well as therapeutic targets. Methods of diagnosis and treatment... Agent: Klarquist Sparkman, LLP

20100202972 - Use of gene variants of the human meis1, btbd9, map2k5, lbxcor1, ptprd or a2bp1 gene for diagnostic and therapeutic approaches to restless legs syndrome (rls): The present invention relates to an oligo- or polynucleotide which can be used in the diagnosis and therapy of restless legs syndrome (RLS). Furthermore, the invention relates to methods of diagnosing a predisposition for or RLS and a method for selecting a therapy to prevent and treat RLS. Moreover, a... Agent: Grant Anderson LLP C/o Portfolioip

20100202974 - Nano-scale contrast agents and methods of use: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.... Agent: Benjamen E. Kern

20100202975 - Novel fluorescent derivatives of polyamines, method for preparing same and applications thereof as diagnosis tools in the treatment of cancerous tumors: The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying... Agent: Birch Stewart Kolasch & Birch

20100202976 - Substance-encapsulating carbon nanohorn aggregate and process for producing the same: A substance-encapsulating carbon nanohorn aggregate which has improved chemical stability by isolating the encapsulated substance from outside and which is useful as a targeting material which can be led from the outside of the body or as a contrast medium by holding the encapsulated substance in an aggregated form, and... Agent: Sughrue Mion, PLLC

20100202979 - Compositions and methods for treatment of pulmonary diseases and conditions: The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The compositions preferably comprise brimonidine and/or dexmedetomidine.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100202978 - Foamable benzoyl peroxide compositions for topical administration: Described herein are benzoyl peroxide compositions useful in the treatment of acne and other skin conditions, which exhibit enhanced stability, even under accelerated conditions. The compositions also exhibit reduced color formation, reduced irritation, and enhanced moisturizing properties. They can be formulated into a topical aerosol foam with inert, non-flammable propellants,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100202977 - Modulation of stat 6 expression for the treatment of airway hyperresponsiveness: Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or... Agent: Knobbe, Martens, Olson & Bear, LLP

20100202981 - Compositions having improved substantivity: The present invention relates to oral care compositions providing improved substantivity to and for the tissues and hard surfaces of the oral cavity.... Agent: Philip S. Johnson Johnson & Johnson

20100202980 - Herbal compositions for the treatment of diabetes and/or conditions associated therewith: The present invention discloses herbal compositions comprising at least one Urtica species or an extract thereof, at least one Artemisia species or an extract thereof, and an extract of at least one Morus species, wherein this extract is prepared of Morus leaves and comprises Morus latex. Further are disclosed methods... Agent: Nixon & Vanderhye, PC

20100202982 - Oral composition containing interferon-alpha: The present invention provides oral compositions which contain interferon α (IFNα) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFNα of the present invention can produce a sufficient effect... Agent: Andrus, Sceales, Starke & Sawall, LLP

20100202983 - Selectively targeted antimicrobials for the treatment of periodontal disease: Compositions and methods for local delivery of selectively targeted antimicrobials are disclosed for the treatment of periodontal disease by eliminating or significantly reducing specific pathogenic bacteria from the bacterial biofilm (plaque) occupying the gingival crevice or periodontal pocket. A carrier agent is utilized to allow for retention, penetration and sustained... Agent: Merchant & Gould PC

20100202988 - Clear carrier compositions containing an alkoxylated monoacid and an alkyl monoamine and method of treating keratinous substrates using such compositions: The present invention relates to compositions comprising: (a) at least one alkoxylated monoacid; (b) at least one alkyl monoamine; (c) at least one lipophilic compound; (d) at least one solvent comprising water; and (e) optionally, at least one auxiliary ingredient, wherein the composition is clear in appearance. Such a composition... Agent: L'oreal Usa Patent Department

20100202986 - Compositions for delivering a drug: A composition comprises a mixture of a silicone and a solvent. The composition further comprises a drug selected from the group of retinoids, retinyls, vitamin A esters, vitamin D analogues, and combinations thereof. The composition further comprises a salt of a dialkyl sulfosuccinate, such as dioctyl sodium sulfosuccinate (DOSS). The... Agent: Howard & Howard Attorneys PLLC

20100202989 - Methods for treatment of dermatological conditions: A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20100202984 - Naphthalene amidine imides: Disclosed are naphthalinamidinimide of formula (I), wherein R1, R2, R3, R4, R5 and R6 independently from each other are hydrogen; or C1-C37alkyl; wherein—one to 10 of the CH2 units of C1-C37alkyl independently from each may be substituted by carbonyl groups; oxygen atoms; sulphur atoms; selenium atoms; tellurium atoms; cis- or... Agent: Basf Performance Products LLC Patent Department

20100202987 - Preparation for improving the protection of human cells, especially cells of the human skin, from the harmful influences of oxidative noxae and uv radiation: The invention relates to topical preparations for improving the protection of the mitochondria of human skin cells from the deleterious influences of oxidative noxae and UV irradiation, said preparations being characterised by a content in proteins that are capable of permeating the mitochondrial membrane. The invention also relates to a... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100202985 - Sunscreen compositions including particulate sunscreen actives that exhibit boosting of sun protection factor: The present invention relates to emulsion-based sunscreen compositions, including only inorganic ultraviolet radiation (UV)absorbers. Specifically, it relates to sunscreen compositions in the form of oil-in-water (O/W) and water-in-oil (W/O) emulsions that contain inorganic UV-absorbers and an SPF-boosting additive. The sunscreen compositions include an emulsion of an oil phase and a... Agent: Marshall, Gerstein & Borun LLP

20100202990 - Powder cosmetic and process for production of flaky calcium sulfate dihydrate to be used in the cosmetic: The invention aims at providing a powder cosmetic which does not suffer from the aggregation of powder even when it contains a large amount of oily component and in which no caking of powder on the surface occurs even when pressed, and a process for the production of platy calcium... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100202992 - Composition containing a liquid fatty phase gelled with a semi-crystalline copolymer: The invention relates to a semi-crystalline copolymer of organic structure with a melting point of greater than or equal to 30° C. obtained from at least two monomers A and B, A being a lipophilic monomer hearing crystallizable side chain(s) and B being an amorphous lipophilic monomer that is copolymerizable... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100202991 - Goniochromatic/light reflective cosmetic makeup compositions: Goniochromatic/light reflecting cosmetic compositions well suited for making up the skin, lips, hair or integuments, contain (a) at least one goniochromatic coloring agent suited for creating a goniochromatic colored background and (b) an amount of light reflective particles suited for creating highlight points that are visible to the naked eye,... Agent: Buchanan, Ingersoll & Rooney PC

20100202993 - Antiperspirant active compositions having sec chromatogram exhibiting high sec peak 4 intensity: An antiperspirant active composition comprising an aluminum salt having an aluminum to chloride molar ratio of about 0.3:1 to about 3:1, exhibiting a SEC chromatogram having a SEC Peak 4 to Peak 3 intensity ratio of at least 7 and a Peak 4 intensity greater than a Peak 5 intensity... Agent: Colgate-palmolive Company

20100202995 - Clear carrier compositions for lipophilic compounds, and method of treating keratinous substrates using such compositions:

20100202994 - Hair treatment compositions: A hair treatment composition comprising at least one lactone in combination with at least one disaccharide.... Agent: Unilever Patent Group

20100202999 - Clear carrier compositions for lipophilic compounds, and method of treating keratinous substrates using such compositions: h

20100202998 - Use of at least one lysine-derived compound for the conditioning of keratinous fibers, cosmetic composition comprising it and method for conditioning the fibers: The present disclosure relates to a method for the conditioning of keratinous fibers comprising applying to dry or wet fibers, a cosmetic composition comprising at least one entity chosen from lysine-derived compounds of formula (I), and the salts and/or solvates thereof. The disclosure also relates to a cosmetic composition for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100203002 - Organopolysiloxane: There is provided an organopolysiloxane which is excellent in extensibility as well as solubility and dispersibility in water and lower alcohols. There is provided an organopolysiloxane with a poly(N-acylalkyleneimine) segment having a repeating unit represented by the following general formula (1): wherein R1 represents a hydrogen atom or an alkyl... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203000 - Clear carrier compositions for lipophilic compounds, and method of treating keratinous substrates using such compositions: e

20100202996 - Wave composition containing a bisulfite compound, a sulfate compound, and a phenol: Disclosed are waving compositions for waving of keratinous fibers, such as hair, containing a) a bisulfite compound, b) a sulfate compound or urea, and c) a phenol, and methods of waving keratinous fibers by applying such compositions to keratinous fibers. Also disclosed is a multi-unit cosmetic kit for treating a... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100203001 - Process for forming disulfide bridges: The present invention relates to an improved method of formation of disulfide bridges in substances bearing SH groups, in particular peptides, for example by formation of intramolecular disulfide bridges, in which a heterocyclic compound having at least one nitrogen atom (e.g. caffeine or a caffeine-like substance) is used for catalysis... Agent: Henry M Feiereisen, LLC Henry M Feiereisen

20100202997 - Cosmetic composition for the hair with a waxy effect, in aerosol form: The disclosure relates to a cosmetic composition for the hair, packaged in an aerosol device, comprising polyols in high concentration together with anionic fixing polymers. It further relates to a cosmetic method for the hair comprising the application of this composition to the hair, and to its use for imparting... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100203003 - Oily hair cosmetics: wherein R1 is an alkylene group having a carbon number of 2-4, which may be mono- or poly-substituted, R2 and R3 are, independently of one another, an alkyl group having a carbon number of 1-4, which may be mono- or poly-substituted, R4 and R5 are, independently of one another, hydrogen... Agent: The Harris Firm

20100203004 - Cosmetic composition containing a tensioning agent and an acrylic polymer: The invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, a skin-tensioning agent and an acrylic polymer containing a group of phosphorylcholine type. The invention also relates to a cosmetic skincare process, more particularly for facial skin, in particular wrinkled skin, comprising the application of the composition... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203005 - Transdermal compositions: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.... Agent: Scully Scott Murphy & Presser, PC

20100203006 - Devolatilization apparatus and process: Embodiments of the invention provide an apparatus or process for devolatilization of flowable materials (such as molten polymers with entrained or dissolved solvent or unreacted monomers or comonomers) using a plate heater having heating channels, the design or operation of which heating channels maintains the flowable material above its bubble... Agent: The Dow Chemical Company

20100203007 - Novel benzodiazepine derivatives: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine... Agent: Sughrue Mion, PLLC

20100203011 - Mammalian cytokines; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Merck C/o Dnax

20100203010 - Modulation of tumor microenvironment: Compositions comprising CD80-targeted therapeutics and methods of using these compositions are provided for the treatment of a disease or disorder in which CD80-expressing cells or regulatory T cell function contribute to or exacerbate the associated pathology.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100203008 - Novel compositions for the treatment of verious inflammatory conditions: The invention relates to compositions for the treatment of inflammatory conditions. The compositions are vaccines comprising IL-18 or fragments thereof.... Agent: Bacon & Thomas, PLLC

20100203009 - Pathway for th-17 cell development and methods utilizing same: The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4+ T cell lineage with unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a... Agent: Bradley Arant Boult Cummings LLP Intellectual Property Department

20100203015 - Carba-nucleoside analogs for antiviral treatment: Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.... Agent: Gilead Sciences Inc

20100203012 - Iap bir domain binding compounds: o

20100203013 - Treating hepatitis c virus infection: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HCV release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.... Agent: Richard Aron Osman

20100203014 - Zwitterionic buffered acidic peptide and protein formulations: The present invention provides glycine buffered pharmaceutical compositions suitable for nasal administration and methods for nasal delivery of such compositions. The pharmaceutical compositions described herein include a therapeutically active peptide and/or protein admixed with an aqueous solution buffered with glycine and having a pH in the ranging from about 3.0... Agent: Dla Piper LLP (us)

20100203017 - Cladribine regimen for treating multiple sclerosis: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100203016 - Pregnancy hormone combination for treatment of autoimmune diseases: The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune... Agent: Mcdermott, Will & Emery LLP Attn:IPDepartment

20100203024 - Sickled erythrocytes, nucleated precursors & erythroleukemia cells for targeted delivery of oncolytic viruses, anti-tumor proteins, plasmids, toxins, hemolysins & chemotherapy: The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with SS or SA hemoglobin or erythroleukemia cells stably transfected with BCAM/Lu which are capable of selectively localizing in tumor vasculature promoting ischemia and occlusion and carrying oncolytic viruses, antitumor proteins, plasmids, toxins and chemotherapy into the... Agent: Central Coast Patent Agency, Inc

20100203018 - Zinc-enriched biomass, method for the preparation thereof and pro-biotic, cosmetic, dietary and nutraceutic products comprising the same: The invention relates to a zinc-enriched biomass comprising living or subsequently killed micro-organisms, selected from the group consisting of Streptococcus thermophilus and Bifidobacterium animalis subsp. lactis and combinations thereof, a method for the manufacture of said zinc-enriched biomass, as well as food preparations, nutraceutic products, functional foods, cosmetic and cosmeceutic... Agent: Steinfl & Bruno

20100203025 - Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well Again,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100203026 - Probiotics for inducing satiety and/or satiation: The invention relates to the field of nutrition and medicine. Provided are compositions, bacterial strains and methods for inducing or enhancing satiety and satiation and for treating or preventing obesity, overweight and overweight related diseases.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100203019 - Podoviriedae bacteriophage having killing activity specific to staphylococcus aureus: The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and... Agent: Ballard Spahr LLP

20100203023 - Enhanced compositions containing cells and extracellular matrix materials: Described are medical graft materials and devices having improved properties relating to their component profiles.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20100203022 - Methods and compositions for delivering therapeutic agents to the central nervous system: Methods are provided for targeting therapeutic agents to an injury site within the central nervous system.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20100203020 - Methods of generating, repairing and/or maintaining connective tissue in vivo: This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in... Agent: Cooper & Dunham, LLP

20100203021 - Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom: The present invention relates to cardiomyocyte progenitor cells (CMPCs), to methods for their isolation and to the use of this CMPCs for the provision of cardiomyocytes, by way of differentiating the obtained CMPCs with a demethylating agent. The present invention also relates to pharmaceuticals compositions comprising cardiomyocytes for use in... Agent: Morrison & Foerster LLP

20100203027 - Viral vector for gene therapy: An objective of the present invention is to provide safe viral vectors for gene therapy that can be introduced by a simple technique and sufficiently express genes of interest in vivo. The present inventors demonstrated that anti-tumor effect can be produced when a heparin-binding cytokine such as granulocyte macrophage colony... Agent: Clark & Elbing LLP

20100203028 - Antimicrobial compositions: An antimicrobial composition is provided having a mole ratio of equivalents of silver ion to equivalents of anion of greater than 1. The invention further relates to antimicrobial compositions composed of silver ions and silver salt particles. Also provided are methods for using the compositions of the invention for the... Agent: Winstead PC

20100203029 - Lysyl oxidase-like 1 (loxl1) and elastogenesis: Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers.... Agent: Fish & Richardson PC

20100203030 - Pharmaceutical formulation: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.... Agent: Morrison & Foerster LLP

20100203031 - Method for enhancing the cleavage activity of i-crei derived meganucleases: A method for enhancing the cleavage activity of an I-CreI derived meganuclease, comprising the site-specific mutation of at least one amino acid residue which is selected in the group consisting of: the glycine at position 19, the phenylalanine at position 54, the phenylalanine at position 87, the serine at position... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203032 - Orlistat compositions: A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.... Agent: Glaxosmithkline Corporate Intelletual Property - Uw2220

20100203033 - Kits, formulations and solutions having enzymatically- permissive amounts of visualization agents and uses thereof: The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or methods for promotion of... Agent: Philip S. Johnson Johnson & Johnson

20100203034 - Methods for the treatment and prevention of diseases of biological conduits: Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall... Agent: Dechert LLP

20100203039 - 3-aminocyclopentanecarboxamides as modulators of chemokine receptors: t

20100203035 - B7-h3 in cancer: Methods of determining the prognosis of a subject with cancer and determining risk of cancer progression by assessing expression of B7-H3. Methods of reducing B7-H3 levels and/or activity.... Agent: Fish & Richardson P.C.

20100203037 - Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in... Agent: Fish & Richardson P.C.

20100203038 - Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual: The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in... Agent: Fish & Richardson P.C.

20100203036 - Targets for tumor growth inhibition: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that... Agent: Ropes & Gray LLP

20100203041 - Antibodies to egfl7 and methods for their use: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20100203044 - Dr6 antagonists and uses thereof in treating neurological disorders: Methods and compositions comprising DR6 antagonists for use in treating neurological disorders, including Alzheimer's disease, are provided. The DR6 antagonists include anti-APP antibodies, anti-DR6 antibodies, DR6 immunoadhesins and DR6 variants (and fusion proteins thereof) which enhance growth, regeneration or survival of mammalian neuronal cells or tissue.... Agent: Genentech, Inc.

20100203045 - Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function.... Agent: Medimmune, LLC Patrick Scott Alban

20100203046 - Fc gamma receptor-binding polypeptide variants and methods related thereto: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20100203040 - Genetic products which are differentially expressed in tumors and use thereof: The invention relates to the identification of genetic products expressed in association with tumours and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumours, proteins, polypeptides and peptides which... Agent: Wayne A. Keown Keown & Associates

20100203049 - Interleukin-10 antibodies: The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.... Agent: Merck C/o Dnax

20100203048 - Methods of using corticotropin-releasing factor for the use of the treatment of cancer: Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).... Agent: Jones Day

20100203047 - Novel compositions and methods for stimulating erythropoiesis in a mammal: The present invention relates to compositions comprising an agent which activates herpes virus entry mediator (HVEM). The present invention also relates to compositions comprising an agonist of HVEM. The present invention also relates to methods of stimulating erythropoiesis in a mammal, comprising administering to a mammal a composition comprising an... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100203042 - Recombinant anti-vla4 antibody molecules: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites... Agent: Steptoe & Johnson LLP

20100203043 - Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr): The present invention relates to a method for the treatment, prevention and/or diagnosis of metastatic prostate cancer. More specifically inhibitors of Epidermal Growth Factor Receptor (EGFR) are used in the preparation of a pharmaceutical composition for treating or preventing metastatic prostate cancer. The EGFR inhibitors can for instance be EGFR... Agent: Amster, Rothstein & Ebenstein LLP

20100203052 - Binding domain-immunoglobulin fusion proteins: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine... Agent: Seed Intellectual Property Law Group PLLC

20100203051 - Diagnostic markers for ankylosing spondylitis and uses thereof: Disclosed are methods and agents for detecting the presence or diagnosing the risk of ankylosing spondylitis (AS) in mammals. These methods are based on the detection of polymorphisms within any one or more of the ARTS-1 gene, the IL-23R gene, the TNFR1 gene locus, the TRADD gene locus and the... Agent: Knobbe Martens Olson & Bear LLP

20100203050 - Erythropoietin fusion protein: The present invention relates to recombinant fusion proteins wherein erythropoietin (EPO) is linked via its C-terminus to an Fc fragment, and wherein said recombinant fusion proteins are further carbamoylated at the primary amines of the fusion protein. More specifically the invention relates to carbamoylated EPO-Fc fusion proteins, wherein at least... Agent: Oliff & Berridge, PLC

20100203053 - Method and composition for treating immune complex associated disorders: The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e.g., cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD. The invention is based upon the surprising finding that chromatin-containing immune... Agent: Wolf Greenfield & Sacks, P.C.

20100203054 - Wnt proteins and detection and treatment of cancer: The present specification provides, inter alia, methods of using Wnt and FZD proteins and genes, and Wnt- and FZD-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver... Agent: Fish & Richardson PC

20100203056 - Anti-pd-l1 antibodies and their use to enhance t-cell function: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.... Agent: Genentech, Inc.

20100203055 - Hair regrowth promoter: It is intended to provide a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia by determining an endogenous factor that inhibits hair growth and screening for substances that inhibit the activity or expression of the endogenous factor. It has been found that FGF18 inhibits hair growth.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100203057 - Novel compounds: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.... Agent: Seed Intellectual Property Law Group PLLC

20100203058 - Diagnostics and therapeutics based on circulating progenitor cells: Methods and compositions for detection, diagnosis, and therapeutics of arterial diseases based on pro-angiogenic and non-angiogenic circulating hematopoietic stem and progenitor cells (CHSPCs) and circulation endothelial colony forming cells (ECFCs) are described.... Agent: Barnes & Thornburg LLP

20100203059 - Method of treating a pathological syndrome and a pharmaceutical agent: Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a... Agent: Kaplan Gilman & Pergament LLP

20100203060 - Inhibitors for growth hormone and related hormones, and methods of use thereof: The present invention encompasses novel inhibitors for growth hormone and related hormones, including prolactin, and placental lactogen, and other hormones. The invention specifically encompasses antibodies, antibody fragments, and modifications thereof, as well as polynucleotides, such antisense polynucleotides, interfering RNAs, and small interfering RNAs, and uses thereof, for inhibition of one... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100203062 - Methods and compositions for treatment of neovascularization: Disclosed herein are methods and compositions for treatment of neovascularization, in particular, ocular neovascularization and resultant fibrotic damage. Compositions comprise inhibitors of the activity of one or more lysyl oxidase-type enzymes, and the methods include methods for making the inhibitors and methods for administration of the inhibitors to a subject... Agent: Arresto Biosciences Bozicevic, Field & Francis LLP

20100203061 - Prevention and treatment of retinal ischemia and edema: The present invention relates to methods of treating retinopathy, retinal ischemia and/or retinal edema comprising administering an integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100203063 - Pestivirus species: The application relates to a pestivirus, designated PMC virus, that is associated with porcine myocarditis syndrome, and the gene and protein sequences derived therefrom. The application further relates to detection methods, vaccine therapeutics, and diagnostic methods using the PMC virus or gene/protein sequences derived therefrom.... Agent: Knobbe Martens Olson & Bear LLP

20100203065 - Human liver regeneration associated protein and the use thereof: This invention provides a novel human liver regeneration associated protein hLRTM4 and the polynucleotide which encodes the hLRTM4 protein. Furthermore, this invention provides a method of preparing and using hLRTM4 protein, and its polynucleotides. hLRTM4 protein can be used to treat liver injury, and its antagonists (e.g. antisense nucleic acids... Agent: Osha Liang L.L.P.

20100203064 - Methods and compositions for modulating wound repair: The present invention relates to a method of modulating repair of a wound. The method includes modulating expression and/or activity of Flightless I in cells involved in repair of the wound.... Agent: Hovey Williams LLP

20100203066 - Polymeric linkers containing pyridyl disulfide moieties: The present invention provides polymeric linkers containing pyridyl disulfide moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20100203067 - Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition... Agent: Grant Anderson LLP C/o Portfolioip

20100203068 - Methods of switching the phenotype of t cells by transgenic lineage factor foxp3: In one aspect the invention relates to a method of switching the phenotype of a target cell, said method comprising inducing lineage factor activity in said cell via a transgene. In another aspect, the invention relates to a method of switching the phenotype of a target cell, said method comprising... Agent: Nixon Peabody, LLP

20100203069 - Antisense respiratory syncytial virus vaccine and therapy: A method is provided for immunizing against pulmonary inflammation and airway hyperresponsiveness associated with infantile RSV infection. This method includes administering an antisense oligonucletide to a subject in need thereof.... Agent: Adams And Reese LLP

20100203070 - Contiguous overlapping peptides for treatment of birch pollen allergy: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of birch pollen Bet v 1. Such peptides while providing all potential T cell epitopes are devoid of the 3D structure of the original allergen, therefore reducing... Agent: Marshall, Gerstein & Borun LLP

20100203071 - Chimeric antigens: Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include in an N-terminal to C-terminal direction: a first F protein polypeptide domain; a G protein polypeptide domain; and a second F protein polypeptide domain. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100203072 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Buchanan, Ingersoll & Rooney PC

20100203073 - Hsv-1 epitopes and methods for using same: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic... Agent: Karen S. Canady Canady & Lortz LLP

20100203074 - Compositions and methods for treating intracellular diseases: The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of... Agent: Novartis Vaccines And Diagnostics Inc.

20100203075 - Chlamydia antigens: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Chlamydia species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Chlamydia species, as well as fragments and variants thereof, a process... Agent: Clark & Elbing LLP

20100203076 - Complexes of rna and cationic peptides for transfection and for immunostimulation: The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg)l; (Lys)m; (His)n; (Orn)o; (Xaa)x with... Agent: Connolly Bove Lodge & Hutz, LLP

20100203077 - Compositions and methods for treating skin with extract from trametes: Compositions for treating skin containing at least one extract from the genus Trametes and at least one viscosity enhancing synthetic polymer, and methods for whitening skin, treating skin for improvement, or treating skin disorders associated with pigmentation such as uneven pigmentation, skin mottling, or age spots or other dermatological disorders... Agent: The Estee Lauder Cos, Inc

20100203078 - Anti-obese compositions containing holoptelea integrifolia extracts: The present invention discloses the extracts of Holoptelea integrifolia or the purified fractions isolated there from and the dietary, nutraceutical and pharmaceutical compositions comprising the same or optionally in combination with one or more known anti-obesic agents useful for the purpose of inhibition, amelioration or prevention of adipogenesis and lipolysis... Agent: Kramer & Amado, P.C.

20100203079 - Ophthalmic composition containing xanthan gum and amino acid: The present invention provides an ophthalmic composition containing xanthan gum, or xanthan gum and an amino acid, which has a superior corneal epithelial disorder-treating effect and a superior corneal epithelial cell-protecting effect.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100203080 - Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof: The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as... Agent: Morgan Lewis & Bockius LLP

20100203081 - Viral inhibitory nucleotide sequences and vaccines: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining... Agent: Wilmerhale/new York

20100203082 - Virus-modified bacteria ghosts: The invention relates to virus-modified bacteria ghosts and the use thereof, for example, as carrier and targeting vehicles for active ingredients.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100203083 - Mutated structural protein of a parvovirus: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process... Agent: Clark & Elbing LLP

20100203084 - Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator: The present invention provides a method for treating pain in a subject in need of treatment, by administering to the subject a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat pain in the subject. Also disclosed is a method for treating opioid-withdrawal effects in... Agent: Amster, Rothstein & Ebenstein LLP

20100203085 - Toxoplasma gondii vaccines and uses thereof: The present invention provides attenuated Toxoplasma gondii knockout mutants of the de novo pyrimidine synthesis pathway and use of the same in vaccines and methods of providing an immune response and protecting a subject against infection by T. gondii and a non-T. gondii disease.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20100203086 - Attack of tumor cells with missing, low or aberrant mhc expression by combining non mhc-restricted t-cells/nk-cells and mhc-restricted cells: This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100203087 - Chemorepulsion of cells: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.... Agent: Elmore Patent Law Group, PC

20100203091 - Decorative printing on polymeric gel air freshener and methods: The polymeric gel air freshener of this invention contains thermoplastic rubber copolymers, hydrocarbon oil, fragrances and functional additives. The invention further provides methods of making articles manufacture that the gel air freshener includes ornament beads and a string or elastic string through a loop to suspend the air freshener. The... Agent: Paul M. Denk Suite 305

20100203090 - Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight... Agent: Hogan Lovells US LLP

20100203089 - Selective chemokine modulation: The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic... Agent: Young & Thompson

20100203088 - Silver nanoparticle dispersion formulation: A topical semisolid (gel) formulation of nanoparticles of silver comprising about 0.001% w/w to about 1% w/w of silver by weight of the total mass of the formulation with its particle size in the range of 0.1 to 150 nanometer; about 0.5% w/w to about 25% w/w of at least... Agent: Charles Muserlain

20100203096 - Collapsible water-containing capsules: Collapsible water-containing capsule comprising by weight: (a) from about 40% to about 98% of a water phase comprising at least 50% water by weight of the water phase; and (b) from about 0.1% to about 35% of a water repelling silicone elastomer powder comprising 100 weight parts of a spherical... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100203094 - Combination of a microorganism and a phytosphingosine derivative, composition, methods of use: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203092 - Dental, particularly remineralizing composition, effective for pain sensitive teeth, and dental particles, particularly for said composition: The invention relates to a dental, particularly a remineralizing composition, effective for pain sensitive teeth, such as toothpaste, tooth powder, mouth wash, chewing gum, dental formulations or the like, comprising spherical dental particles having a particle size between 0.1 and 2 μm made of silica gel in an one-part combination,... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20100203097 - Foundation compositions comprising water repelling silicone elastomer powders: Cosmetic foundation compositions comprising: (a) from about 0.1% to about 85% of a water repelling silicone elastomer powder comprising 100 weight parts of a spherical silicone elastomer particle and 0.5-25 weight parts of polyorganosilsequioxane for coating the spherical silicone elastomer particle; wherein the water repelling silicone elastomer powder does not... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100203093 - Interference pigments on the basis of perlite flakes: The present invention relates to pigments, comprising a plate-like substrate of perlite, and (a) a dielectric material, especially a metal oxide, having a high index of refraction; and/or (a) a metal layer, especially a thin semi-transparent metal layer; a process for their production and their use in paints, ink-jet printing,... Agent: Basf Performance Products LLC Patent Department

20100203095 - Water-repellent fine particles and making method: Silicone elastomer spherical particles having a volume mean particle size of 0.1-100 μm are coated with a polyorganosilsesquioxane and washed with alcohol or a mixture of alcohol and water. The coated fine particles are water repellent so that they are non-dispersible in water and float on water.... Agent: Birch Stewart Kolasch & Birch

20100203098 - Dust composition for combating insects: The present invention relates to a dust composition comprising at least one insecticide selected from GABA antagonists and at least one organic carrier selected from celluloses and cellulose derivatives. The invention further relates to the use of the dust composition for combating insects and to a method for controlling insects... Agent: Brinks, Hofer, Gilson & Lione

20100203099 - Multi-domain amphipathic helical peptides and methods of their use: Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent... Agent: Klarquist Sparkman, LLP (ott-nih)

20100203100 - Antimicrobial accessory for an implantable medical device: An antimicrobial accessory may include a pressure sensitive adhesive and an antimicrobial mixed in the pressure sensitive adhesive. In some examples, an antimicrobial accessory may include at least one first domain comprising a pressure sensitive adhesive and a first antimicrobial and at least one second domain including a second polymer... Agent: Medtronic, Inc.

20100203101 - Bio-membrane for tissue regeneration: A bio-membrane with angiogenic activity for implant in tissue regeneration and repair, including bone reconstruction and the repair of skin and soft tissue lesions is described, essentially constituted by a gel able to provide support and growth and/or differentiation and/or angiogenic factors for the full in vivo functionality of the... Agent: Kenneth Sharples

20100203102 - Compositions and methods for treating post-operative pain using bupivacaine and an anti-onflammatory agent: Effective treatments of pain that accompanies post-operative surgeries are provided. Through the administration of an effective amount of a combination of bupivacaine and an anti-inflammatory agent at or near a target site, one can alleviate or prevent pain while preventing undesirable levels of inflammation. This administration of bupivacaine and an... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100203103 - Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues: The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100203104 - Delivery system for risperidone: This invention relates to an extended release formulation comprising solid risperidone, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing risperidone. The polymer is preferably made of ethylene-vinyl acetate copolymer.... Agent: Organon Usa, Inc. C/o Merck

20100203105 - Method for administering insulin to the buccal region: A mixed micellar pharmaceutical formulation includes a micellar pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compound. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100203106 - Method for encapsulating amino acids, vitamins and medications and method for increasing rumen bypass of amino acids, vitamins and medications: A method for encapsulating amino acids, vitamins and/or medications where the rumen bypass of the amino acids, vitamins and/or medications is increased. Ruminant supplements produced by the method for encapsulating, methods for producing milk and methods for increasing the production of milk protein.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100203107 - Methods of administering a dermatological agent to a subject: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of... Agent: Bozicevic, Field & Francis LLP

20100203108 - Patch and patch preparation: The present invention provides to a patch and a patch preparation having low stretchability, which can be continuously adhered to the skin for a long time without undesirable detachment and marked falling off from the skin due to various factors during adhesion, and specifically provides a low stretchable patch and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100203112 - Composition of cationic phospholipid nanoparticles for effective delivery of nucleic acids: The present invention provides a cationic phospholipid liposome composition comprising 1,2-dioleoyl-sn-glycero-S-ethylphosphocholine (EDOPC), 3β-[N—(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-cholesterol) and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE), a liposome-nucleic acid complex which is capable of forming a complex therewith, and a pharmaceutical composition comprising the same. The cationic phospholipid liposome of the present invention is highly effective for intracellular... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100203111 - G-substrate for the treatment and prevention of parkinson's disease: The invention features methods and compositions for the treatment and prevention of Parkinson's Disease.... Agent: Foley & Lardner LLP

20100203109 - Methods and compositions for treating melanoma: Novel BRAFV600E mutant peptides or a pharmaceutically acceptable salt thereof, that induce MHC Class I-dependent cytotoxic T cell responses in mammals are useful in prophylactic, diagnostic and therapeutic treatments for melanoma. Such compounds are also useful in drug development for non-peptide mimics of the compounds described herein and in the... Agent: Howson & Howson LLP

20100203114 - Micelle encapsulation of therapeutic agents: The invention provides 17 AAG encapsulated in micelle particles. The micelles can be comprised of safe poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA). A significant advantage of PEG-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO. Additionally, PEG-PLA micelles are easier to handle than DMSO and they... Agent: Schwegman Lundberg & Woessner/warf

20100203115 - Organic-inorganic hybrid material for the storage and release of active principles: e

20100203110 - Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production: The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that... Agent: Foley Hoag, LLP (w/jhv)

20100203116 - Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo: The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100203113 - Wnt signalling inhibitors, and methods for making and using them: The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100203117 - Anti-adipogenic compositions containing piper betle and dolichos biflorus: Herbal compositions are useful for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. The herbal compositions comprise biologically effective amounts of extracts or fractions from Piper betle in combination with one or more of the extracts or fractions derived from Dolichos biflorus,... Agent: Kramer & Amado, P.C.

20100203118 - Collapsible water-containing capsules: Collapsible water-containing capsules comprising by weight: (a) from about 40% to about 95% of a water phase the water phase comprising at least 50% water by weight of the water phase; and (b) from about 5% to about 20% of a spindle-shaped metal oxide powder which is hydrophobically surface-treated and... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100203119 - Pharmaceutical treatment process using chitosan or derivative thereof: l

20100203120 - Pharmaceutical cyclosporin compositions: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].... Agent: Klarquist Sparkman, LLP

20100203121 - Formation of nanometric core-shell particles having a metal oxide shell: (a) preparing an oil-in-water emulsion by emulsification of an oily phase that comprises a core material, in an aqueous phase, under high shear forces, wherein one or both of the oily phase, and the aqueous phase comprises a sol-gel precursor; (b) subjecting the emulsion obtained in (a) to a high... Agent: Oliff & Berridge, PLC

20100203122 - Delivery system for remote treatment of an animal: A remote treatment delivery system comprising a substantially non-skin piercing dosage projectile containing a biologically active agent and a transdermal carrier.... Agent: Morgan Lewis & Bockius LLP

20100203124 - Kappa-2 carrageenan composition and products made therefrom: The present invention is directed to a kappa-2 carrageenan composition comprising: (i) kappa-2 carrageenan, (ii) at least 70% sodium by weight of all cations in the composition; and (iii) free salt present in an amount of 0-25% by weight of the composition; wherein the composition has a viscosity of 20... Agent: Patent Administrator Fmc Corporation

20100203123 - Methods for improving cognitive function and decreasing heart rate: The present invention is directed to methods of improving cognitive function in subjects having age related cognitive decline or mild cognitive impairment and to methods of decreasing heart rate in a subject by administering dosage forms comprising docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA).... Agent: Dechert LLP

20100203127 - Large dose ribavirin formulations: The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.... Agent: Arent Fox LLP

20100203126 - Multilayered vitamin complex tablet containing ubidecarenone: The present invention relates to a multi-layered vitamin/mineral complex tablet having enhanced stability of ubidecarenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients decreasing the stability of ubidecarenone are contained in an additional layer separated from the first layer. The method is... Agent: Dickstein Shapiro LLP

20100203125 - Synergistic antibacterial formulation and a method of making the same: An antibiotic formulation including penicillinase resistant penicillin, cefixime trihydrate, lactobacillus and pharmaceutically acceptable excipients. The penicillinase resistant penicillin is in two forms, sustained release and immediate release.... Agent: Lucas & Mercanti, LLP

20100203128 - Bupropion hydrobromide and therapeutic applications: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203129 - Controlled release formulations with continuous efficacy: The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an... Agent: Stoel Rives LLP - Slc

20100203131 - Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight... Agent: Hogan Lovells US LLP

20100203133 - High drug load tablet:

20100203132 - Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1 receptor antagonists: A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.... Agent: Crowell & Moring LLP Intellectual Property Group

20100203130 - Pharmaceutical compositions resistant to abuse: The present invention provides immediate release pharmaceutical compositions for Oral administration that are resistant to abuse.... Agent: Stoel Rives LLP - Slc

20100203134 - Spheroids and multiparticulate tablets comprising them: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of... Agent: Buchanan, Ingersoll & Rooney PC

20100203138 - controlled release composition comprising a recombinant gelatin: e

20100203137 - Formulation of meningitis vaccines: A liquid Hib component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined meningitis vaccine. A lyophilised meningococcal component can also be reconstituted with an oil-in-water emulsion.... Agent: Novartis Vaccines And Diagnostics Inc.

20100203136 - Method for delivering a human chorionic gonadotropin (hcg) vaccine for long-acting antibody protection: This invention comprises a method of immunization in which human chorionic gonadotropin (hCG) vaccine antigens are incorporated into an inorganic salt/biopolymer complex using a simple manufacturing process. The resulting solid matrix is administered to human subjects in the form of microparticles. The method comprises suspending microparticles in an emulsion of... Agent: C. Rachal Winger C/o Ocip Group

20100203140 - Methods, compositions, and kits for organ protection during systemic anticancer therapy: Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.... Agent: Fanelli Strain & Haag PLLC

20100203139 - Nanoemulsion therapeutic compositions and methods of using the same: The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising... Agent: Casimir Jones, S.c.

20100203135 - Skin equivalent culture: Methods of forming soft connective tissue compositions such as skin equivalents, compositions made by the methods and their uses. In particular, a method of forming a connective tissue equivalent, comprising the steps of: (i) incubating collagen-producing cells in or on a support matrix; (ii) inducing and/or enhancing collagen production by... Agent: Fulbright & Jaworski L.L.P.

20100203141 - Stimuli-responsive low solubility hydrogel copolymers of n-isopropyl acrylamide and synthesis method: Preferred embodiment stimuli-responsive low solubility copolymer hydrogel compositions of the invention include polymerized N-isopropylacrylamide and water insoluble monomer or oligomer repeating units. The repeating units are arranged within the polymer backbone of the copolymer hydrogel. In a preferred fabrication method, precursors of N-isopropylacrylamide and precursors of the water insoluble monomer... Agent: Greer, Burns & Crain

20100203142 - Amphiphilic compound assisted nanoparticles for targeted delivery: The present invention generally relates to nanoparticles with an amphiphilic component. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together... Agent: Pabst Patent Group LLP

20100203145 - Continuous process for microspheres production by using expanded fluids: The process is carried out in a counter-current packed column wherein the expanded emulsion is fed from the top, while the expanded liquid is fed from the bottom. Thanks to the presence of the expanded liquid, any deposition of the solid particles produced on the packing elements is avoided, thus... Agent: Arent Fox LLP

20100203144 - Immobilized metallic nanoparticles as unique materials for therapeutic and biosensor applications: The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles.... Agent: University Of Virginia Patent Foundation

20100203146 - Intermittent dosing strategy for treating rheumatoid arthritis: The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate, gold compounds, antimalarials, cyclosporine A, leflunomide, azathioprine, sulfasalazine... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100203143 - Systems and methods for nanomagnetic actuation of molecular cell signaling: The present invention relates to signaling mechanisms that transduce magnetic inputs into physiological cellular outputs. More particularly, the present invention relates to systems and methods for non-invasively controlling cellular signaling functions and behaviors by harnessing receptor-mediated and intracellular molecular-mediated signal transduction using nanomagnetic cellular switches.... Agent: David S. Resnick

20100203147 - Viruses for the treatment of cellular proliferative disorders: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus,... Agent: Fish & Richardson P.C.

20100203148 - Encapsulation and controlled release of small molecules for intracellular delivery using thermally responsive nanocapsules: In accordance with certain embodiments of the present disclosure, a method for intracellular delivery of small molecules is provided. The method includes encapsulation of small molecules in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule and allowing the small molecules... Agent: Dority & Manning, P.A.

20100203151 - Microspheres having core/shell structure: Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension... Agent: Sughrue Mion, PLLC

20100203152 - Mixed metal compounds used as antacids: There is provided use of a mixed metal compound in the manufacture of medicament for neutralising or buffering stomach acid, wherein the mixed metal compound contains at least one trivalent metal selected from iron (III) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium,... Agent: Mayer Brown LLP

20100203149 - Nanoparticles for cytoplasmic drug delivery to cancer cells: The invention is a nanoparticle that contains an anticancer drug that is released in cancer cells when administered to a subject. The nanoparticles have a core including the anticancer drug and polymer chains that are soluble at the pH of the cancer cell. The core is surrounded by a layer... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20100203150 - Novel amphiphilic copolymers and fabrication method thereof: The present invention discloses a comb-like amphiphilic copolymer comprising a hydrophilic segment and a hydrophobic segment. It also discloses a novel fabrication method for synthesizing said amphiphilic copolymers. A novel initiator comprising a drug molecule, e.g. 5′-DFUR, bonded to one or two macromolecules of a hydrophobic polymer is provided. A... Agent: Bacon & Thomas, PLLC

20100203153 - Sustained-release nanoparticle compositions and methods using the same: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.... Agent: Dann, Dorfman, Herrell & Skillman

20100203154 - Elasmobranch-repelling compounds, methods of use and devices: Elasmobranch-repelling compositions are prepared from elasmobranch carcasses. Extraction of these elasmobranch carcasses with polar solvent after a period of aerobic decay yields semiochemical repellents that induce a flight reaction in sharks when introduced into the sharks' oceanic proximity.... Agent: Kenyon & Kenyon LLP

20100203155 - Segmented delivery system: A covering for delivering a substance or material to a surgical site is provided. The covering, with substance provided therein, may be referred to as a delivery system. Generally, the covering may be a single or multi-compartment structure capable of at least partially retaining a substance provided therein until the... Agent: Dorsey & Whitney LLP Intellectual Property Department

20100203156 - Xenon as a treatment for hemoglobinopathy: The method disclosed herein entails treating a person, with sickle cell disease and who is suffering a pain crisis, with an effective amount of xenon, which alleviates the pain. Inhalation of xenon at subanesthetic concentrations has significant analgesic properties, which are mechanistically independent from the opioid receptor system. Inhaled xenon... Agent: Brett Bartel

20100203157 - Combinations of pyrimethanil and silver compounds: The present invention relates to combinations of pyrimethanil, or a salt thereof, and silver compounds which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of pyrimethanil, or a salt thereof, together with one or more silver salts selected from silver acetate, silver... Agent: Philip S. Johnson Johnson & Johnson

20100203158 - Antiseptic compositions and uses thereof: Antiseptic compositions and kits containing a source of silver ions and menthol, which act in synergy such that a concentration of silver ions in the composition is substantially reduced, are disclosed. Further disclosed are uses of the antiseptic compositions as disinfectants and in the treatment of wounds.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100203159 - Metal component absorption enhancer in plant: t

20100203160 - Vitamin/mineral composition with dha: Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient... Agent: Wood, Herron & Evans, LLP

20100203163 - Injectable polymer-lipid blend for localized drug delivery: An injectable polymer-lipid blend is provided as a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty acid or a... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20100203162 - Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid: Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.... Agent: Jones Day

20100203161 - Sterilisation and conservation of liquids: The invention relates to products, containing a solid biocide and a composite material (11) for the absorption of contaminants and the release of active ingredients as a composite preparation for the simultaneous, separate or programmed sequential application on sterilisation and long-term conservation of a liquid (6) for purification. According to... Agent: Birch Stewart Kolasch & Birch

20100203164 - Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists: A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms,... Agent: Quarles & Brady LLP

20100203165 - Compositions and methods for treatment of disorders or conditions of the eye: The invention provides compositions comprising low concentrations of selective α-2 adrenergic receptor agonists in combination with potassium and/or calcium. Methods for treating eye disorders and conditions are also provided. The compositions preferably comprise brimonidine.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100203166 - Methods of preventing respiratory infections: Methods for inhibiting the development of respiratory infections in humans are disclosed. One embodiment of the methods comprises pouring a predetermined amount of an oral rinse, capable of rendering ineffective a pathogen which has recently infected the respiratory tract, into the mouth of the human, agitating the oral rinse with... Agent: Moore Patents

20100203167 - Azeotrope compositions comprising decafluoropentane and hydrogen fluoride and uses thereof: Disclosed herein are azeotrope compositions comprising 1,2,3,3,3-pentafluoropropene and hydrogen fluoride. The azeotrope compositions are useful in processes to produce and in processes to purify 1,2,3,3,3-pentafluoropropene. Additionally, disclosed herein are azeotrope and near-azeotrope compositions comprising 1,1,1,2,3,4,4,5,5,5-decafluoropentane and hydrogen fluoride.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100203168 - Bone microenvironment modulated seizure treatments: Novel etiology underlying certain types of seizures is presented, whereby changes in endocrine levels result in changes in osteoclast activity levels which in turn result in elevated extracellular Ca2+ levels which in turn result in systemic alterations in nerves, including increased membrane depolarization and enhanced neurotransmitter release, which in turn... Agent: Mark Zamoyski

20100203169 - Composition and method of treating side effects from antibiotic treatment: A method of treating side effects of antibiotic treatment includes the step of internally administering an antibiotic that is capable of inducing hearing loss in a mammal. The method further includes the step of internally administering a composition to the mammal in conjunction with administration of the antibiotic. The composition... Agent: Howard & Howard Attorneys PLLC

20100203170 - Method for formulating agrochemical active ingredients so as to regulate their release kinetics, protect them from outside stresses, and keep their users safe: The invention pertains to a new method for formulating any agrochemical active ingredient so as to protect the user, protect this active ingredient from outside stresses, and control its release kinetics. It relies on the use of acrylic and thickening emulsions with a pH greater than five and containing hydrophobic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203171 - Therapeutic foam: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100203172 - Sodium nitrite-containing pharmaceutical compositions: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration... Agent: Jones Day

20100203173 - Silica dispersion: Dispersion containing, in addition to water, 0.5 to 20% by weight of hydrophobic silica, 0.01 to 10% by weight of a gelling additive, or viscosity-increasing additive which, as further components, contains at least one phenol or at least one phenol derivative and/or at least one aldehyde. It is prepared by... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100203174 - Pet food composition for regulating body weight and preventing obesity and related disorders in pets: The invention relates to a pet food composition for regulating body weight and preventing obesity and related disorders in pets, which comprises as an active ingredient at least one plant or plant extract having the ability to stimulate energy expenditure and/or fat burning. The invention also relates to a method... Agent: K&l Gates LLP

20100203175 - Deglycation of ages: The invention particularly relates to the use of such a substance for preparing a composition intended to prevent and/or combat a reduction in flexibility and/or plasticity and/or elasticity and/or functionality of a tissue, and/or to prevent and/or combat the ageing of a tissue, by promoting the deglycation of AGEs in... Agent: Basf Beauty Care Solutions France

20100203176 - Method for reducing weight in a subject: A method is provided for reducing weight in a subject by administering an effective amount of a composition comprising omega-3 polyunsaturated fatty acid (PUFA), at least one of L-arginine, L-ornithine, an L-arginine precursor and an L-ornithine precursor, and at least one of a nucleobase, a nucleoside and a nucleic acid.... Agent: Young & Thompson

20100203177 - Use of anabolic agents, anti-catabolic agents, antioxidant agents and analgesics for protection, treatment and repair of connective tissues in humans and animals: The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-a, IL-1 (3, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic... Agent: Arent Fox LLP

20100203178 - Synergistic herbal composition: A present invention relates to the synergistic herbal ophthalmic composition, which delays the onset and progression of cataract. The product is suitable for prophylactic treatment of cataract of different degree. The herbs are cleaned coarsely ground, weighed as per formula and extracted using different solvents preferably water, filtered or centrifuged... Agent: Sughrue Mion, PLLC

20100203179 - Bioactive water fraction from gomphostema niveum: The present invention relates to a novel bioactive water fraction obtained from the leaves of an herb named Gomphostema niveum commonly found in North Eastern part of India, and which is useful for inhibiting the growth of malarial parasite Plasmodium falciparum. The present invention also relates to a method for... Agent: Ladas & Parry LLP

20100203180 - Antimicrobial protein derived from podoviriedae bacteriophage specific to staphylococcus aureus: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition... Agent: Ballard Spahr LLP

20100196264 - Use of somatostatin analogs in myocardial perfusion imaging: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.... Agent: Edwards Angell Palmer & Dodge LLP

20100196265 - Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof: Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100196266 - Humanized anti-hla-dr antibodies: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for... Agent: Immunomedics, Inc.

20100196267 - Humanized l243 antibodies: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.... Agent: Immunomedics, Inc.

20100196268 - Compositions and methods for treatment of tumors by direct administration of a radioisotope: m

20100196269 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ-opioid receptor-mediated diseases, disorders, and/or... Agent: Feldman Gale, P.A.

20100196271 - Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and pet imaging using the same: where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a... Agent: Hogan Lovells US LLP

20100196270 - Radiofluorination methods: The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.... Agent: Ge Healthcare, Inc.

20100196272 - Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-Trehalose to add bulk and to... Agent: Roger A. Gilcrest

20100196273 - Novel agent for in vivo pet imaging of tumor proliferation: Compounds for in vivo diagnostic imaging of cellular proliferation are provided. The compounds include L-nucleosides such as a 2′-deoxy-2′-fluoro-L-ara-binofuranosyl pyrimidine nucleoside analogue. These nucleosides are labeled with a positron emitting radioisotope. The present invention also provides a method for in vivo diagnostic imaging of cellular proliferation.... Agent: NielsenIPLaw LLC

20100196274 - Methods for diagnosing diseases and evaluating treatments therefor using pet: The present invention relates to methods for determining whether a mammal has a disease, such as diabetes, using PET data analysis techniques. These methods include administering to a mammal a PET-compatible tracer, such as a radioligand specific for a vesicular monoamine transporter 2 (VMAT2) receptor, and measuring total functional β-cell... Agent: Bryan Cave LLP

20100196275 - Methods and products for neutralizing the harmful effects of combustion products: The invention relates to the role of Acr-DNA adducts in p53 mutagenesis in CS-related lung cancer. The distribution of Acr-DNA adducts was mapped at the sequence level in the p53 gene of lung cells using the UvrABC incision method in combination with ligation-mediated PCR. It was determined that Acr preferentially... Agent: Klauber & Jackson

20100196277 - Nanoparticle compositions for controlled delivery of nucleic acids: Micro- and nano-particles are molded in micro- and nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The micro- and nano-particles can include pharmaceutical compositions, biologic drugs, drug compositions, organic materials, RNA, DNA, oligonucleotides, and the like.... Agent: Alston & Bird LLP

20100196278 - Photoacoustic imaging agent: A molecular probe marked with a color center material is used as a photoacoustic imaging agent to obtain an acoustic signal of practically adequate intensity using weak near-infrared light, which has good in vivo penetration depth but has small excitation energy, and is within the maximum permissible exposure, in photoacoustic... Agent: Fitzpatrick Cella Harper & Scinto

20100196276 - Recombinant canine thyroid stimulating hormone and methods of production and use thereof: The invention includes a nucleic acid having a sequence at least 98% homologous to SEQ ID NO: 1, which encodes the α subunit of canine thyroid stimulating hormone (TSH). The invention also includes a nucleic acid having a sequence at least 98% homologous to SEQ ID NO: 2, which encodes... Agent: Baker Botts L.L.P.

20100196279 - Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers: Provided is a method of monitoring the treatment of Gaucher disease with specific pharmacological chaperones using systemic and/or cellular surrogate markers. Also provided is a new biomarker that may be used to monitor the progress of such treatment.... Agent: Hoffmann & Baron, LLP

20100196280 - Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications: The present invention describes polymer nanoparticles with a cationic surface potential, in which both hydrophobic and hydrophilic pharmaceutically active substances can be encapsulated. The hydrophilic and thus water-soluble substances are encapsulated in the particle core by co-precipitation through ionic complexing with a charged polymer. Both therapeutic agents and diagnostic agents... Agent: Millen, White, Zelano & Branigan, P.C.

20100196281 - Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent: A method for treating a joint affected by pain that involves injecting an agent that includes resiniferatoxin (RTX) dissolved in a physiologically suitable solvent locally into the intracapsular region or the bursa of the joint affected by pain.... Agent: Rankin, Hill & Clark LLP

20100196283 - Method and imaging medium for use in the method: The invention relates to a method of 13C-MR detection using an imaging medium comprising hyperpolarised 13C-lactate and to an imaging medium containing hyperpolarised 13C1-lactate for use in said method.... Agent: Ge Healthcare, Inc.

20100196284 - Ultrasound imaging with targeted microbubbles: Compositions and methods for detecting various disorders with targeted microbubbles are disclosed. Specifically, microbubbles comprising glycoprotein Ib (GPIb), ligands for VCAM-1, and ligands for P-selectin such as PSGL-1 are disclosed. Also disclosed are methods for using targeted microbubbles to detect cardiovascular disease comprising administering the disclosed microbubbles to a subject... Agent: Dann, Dorfman, Herrell & Skillman

20100196282 - Optical imaging agents: The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of benzopyrylium dyes with biological targeting moieties, such as peptides Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods.... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20100196285 - Use of deuterium oxide to treat virus-based diseases of the respiratory tract: The present invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of virus-based diseases of the respiratory tract.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100196286 - Inhalation delivery methods and devices: Methods, devices and kits for treating sleep disorders, anxiety disorders, and developmental disorders, and/or for inducing an arousable state of sedation in a subject, are described. For example, inhalation methods, devices and kits for treating insomnia, anxiety and/or ADHD using one or more α2-adrenergic agonists such as dexmedetomidine or clonidine... Agent: Morrison & Foerster LLP

20100196287 - Compositions comprising perhydrolases and alkylene glycol diacetates: The present invention relates to compositions, in particular washing and cleaning agents as well as cosmetic and pharmaceutical preparations, comprising perhydrolases and alkylene glycol diacetates.... Agent: Henkel Corporation

20100196288 - Herbal mixture extract of pleurotus eryngii, acanthopanacis cortex and notoginseng radix and a composition comprising the same for prevention and treatment of periodontitis: The present invention relates to a herbal mixture extract of Pleurotus eryngii, Acanthopanacis Cortex and Notoginseng Radix and a composition for prevention and treatment of periodontal disease containing the herbal mixture extract as an active ingredient, more precisely, a herbal mixture extract having activities of inhibiting the generation and activation... Agent: Lucas & Mercanti, LLP

20100196290 - Compositions comprising betulonic acid: The invention relates to compositions of cosmetic and pharmaceutical industries comprising betulonic acid for humans and animals, and further, to the use of betulonic acid in compositions of cosmetic and pharmaceutical industries. The invention is also directed to compositions containing, besides betulonic acid, optionally other compounds derived from betulin.... Agent: Birch Stewart Kolasch & Birch

20100196289 - Double layered oxide and hydroxide pigments and method of their preparation: A pigment having at least two layers according to the following structure (I), where C is an internal pigment core of formula [Mx(O)y(OH)z]; where MX=TiIV, ZnII, ZrIV, SnIV, FeII, FeIII, SnII, CrVI, or MnII; x=2, 3 or 4; and (y/2+z)=x; A is a plant polyphenol having an active-redox, radical scavanger... Agent: Hess Patent Law Firm, P.C.

20100196292 - Hydrophylic silicone elastomers in cosmetics: The invention is directed to the use of a number of hydrophilic silicone elastomers in various cosmetic and personal care products where they serve various functions such as emulsifiers, film forming agents, viscosity stabilizers, conditioning agents and protective barrier forming agents. Emulsions and personal care products based upon same are... Agent: Henry D Coleman

20100196291 - Personal care sunscreen compositions having reduced eye irritation: The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulite composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters... Agent: Philip S. Johnson Johnson & Johnson

20100196293 - Use of an active principle originating from flax in a composition intended to reinforce the barrier function of the skin and to protect the skin and the appendages against external aggressions: The present invention concerns the use, in a cosmetic composition, of an effective quantity of active principle originating from flax (genus Linum) to reinforce the barrier function of the skin and to protect the skin and the appendages against external aggressions. The active principle originates from the hydrolysis of flax... Agent: Young & Thompson

20100196295 - Cleansing compositions: A composition comprising an adduct of an oil and an addition material and a flaxseed extract.... Agent: Colgate-palmolive Company

20100196294 - Coatings for mammalian nails that include nanosized particles: One embodiment described herein includes a mammalian nail enamel. The mammalian nail enamel includes at least one film forming component; at least one plasticizer; at least one solvent; and nanoparticles of one or more of nanoclay, nanosilica, nanopigments or nanoceramics.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100196296 - Multi-layer metallic effect pigments, process for their preparation and use: e

20100196298 - Coloring materials and their use in compositions, in particular cosmetic compositions: The invention relates to a coloring material comprising a colored product bound to a solid substrate in which said colored product is a colored derivative of geniposide and/or genipin and/or geniposidic acid and/or an extract of a plant comprising at least one of the abovementioned products and said solid substrate... Agent: Woodcock Washburn LLP

20100196297 - Urine as a source of alternative cellular energy pigments (ace-pigments) in the assesment and therapy of diseases: Alternative cellular energy pigments (ACE-pigments) are over-produced in response to various types of viral infections and to other pathological conditions. ACE pigments accumulate at the sites of disease and also in other regions of the body, including the oral cavity. ACE pigments are considered to play a significant role in... Agent: William John Martin

20100196299 - Antiperspirant products: Antiperspirant products are described that include a dispensing package and an antiperspirant product contained within a chamber component of the dispensing package. The portion of the chamber component that comes into contact with the antiperspirant composition is made from a polymeric resin that is substantially devoid of phosphorus compounds.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100196300 - Basic aluminum nitrate: A basic aluminum composition comprising an empirical formula: Al2(OH)6—aXa where 0.5≦a≦5.0, and X is an anion of nitrogen; and wherein the composition possesses an NMR spectrum in which a −40 to +40 ppm resonance line comprises at least 60% of the total area of the NMR spectrum.... Agent: W.r. Grace & Co.-conn.

20100196301 - Hair care compositions: The invention provides a hair care composition comprising: (i) emulsified particles of an alkyl modified silicone, and (ii) emulsified particles of a non-volatile, non-alkyl modified silicone. The compositions are particularly suitable for use asa conditioner for the treatment of hair (typically after shampooing) and subsequent rinsing. Compositions according to the... Agent: Unilever Patent Group

20100196302 - Keratin hydrolysates, process for their production and cosmetic composition containing the same: This present invention provides a process for keratin hydrolysis by means of microbiological and/or enzymatic processes. In particular, the keratin is derived from feathers of animals, such as chicken and are submitted to hydrolysis by a strain of Bacillus sp. The hydrolysates have molecular weight lower than 500 Da, which... Agent: Alston & Bird LLP

20100196303 - Method of treating hair: A method of hair styling or straightening comprising: i) a straightening active selected from adenine, guanine or derivatives thereof.... Agent: Unilever Patent Group

20100196304 - Polyglycerol silicone polymers in personal care: The present invention relates to a series of novel silicone polyesters that are prepared by crosslinking an dimethicone copolyol, polyglycerol dimer acid. The nature of the silicone group, the water loving polyglycerol group as well as the fact that a C-36 fatty diacid is used in preparation of the products... Agent: Anthony J. O' Lenick, Jr.

20100196305 - Sulfone polymer compositions: Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi-amine monomer and a multifunctional sulfonyl-containing monomer... Agent: Genzyme Corporation Legal Department

20100196306 - Bioactive aniline copolymers: Aniline copolymers and the synthesis thereof for use as antimicrobial (antibacterial, antifungal or antiviral material) material of for the manufacture of antimicrobial objects, suitable for use in the health, food, packaging, water, paint, wood, textile, poultry, glass, paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. The copolymer may be... Agent: Edwards Angell Palmer & Dodge LLP

20100196307 - Attractant for indian meal moth larve: A composition containing 2-pentylfuran is an effective attractant for the larvae of the Indian meal moth (Plodia interpunctella). The composition may be used alone or with a carrier component. The composition may be used in combination with any insect trapping means known in the art, as required for a specific... Agent: Usda, Ars, Ott

20100196308 - Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy: The present disclosure relates to the use of vitamin D compounds, such as vitamin D3, or analogs and/or metabolites thereof, to modulate bone marrow progenitors and stromal cells prior to the administration of antineoplastic agents. The methods of the present disclosure may ameliorate myelosuppression by increasing the availability of pluripotent... Agent: Mccarter & English, LLP Boston

20100196312 - Glycosylated il-7, preparation and uses: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100196315 - Il-12/p40 binding proteins: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro... Agent: Yankwich & Associates, P.C. (and Abbott Bioresearch Center)

20100196309 - Interleukin-21 variants with altered binding to the il-21 receptor: The invention is concerned with IL-21 polypeptide variants having an altered binding to the common gamma chain (c) of the IL-21 receptor and the use thereof in therapy.... Agent: Woodcock Washburn LLP

20100196311 - Methods and compositions containing mtor inhibitors for enhancing immune responses: Provided are compositions and methods for enhancing immune responses to an antigen. The compositions contain an isolated population of CD8+T cells and an inhibitor of mammalian target of rapamycin (mTOR). The method for obtaining an enhanced immune response to an antigen in an individual entails administering to the individual the... Agent: Hodgson Russ LLP The Guaranty Building

20100196310 - Methods of treating cancer by administering human il-18 combinations: The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100196313 - Modified two-component gelation systems, methods of use and methods of manufacture: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first... Agent: Abbott Cardiovascular Systems Inc./bstz Blakely Sokoloff Taylor & Zafman LLP

20100196314 - Modified two-component gelation systems, methods of use and methods of manufacture: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first... Agent: Abbott Cardiovascular Systems Inc./bstz Blakely Sokoloff Taylor & Zafman LLP

20100196316 - Cyclosporin analogues for preventing or treating hepatitis c infection: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.... Agent: Elmore Patent Law Group, PC

20100196317 - Cyclic undecapeptides and derivatives as multiple sclerosis therapies: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of a cyclosporin compound.... Agent: Klarquist Sparkman, LLP

20100196318 - Methods of treating inflammatory and autoimmune diseases with natalizumab: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease; and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100196319 - 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections: t

20100196321 - Compounds: The present invention features compounds of Formula (I) and (Ia), pharmaceutical compositions and use in the treatment of viral disease:... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100196320 - Interferon aplpha sequential regimen for treating cancers: The present invention relates to a method of treating cancers, especially those showing resistance to classical anti-pro liferative chemotherapy drugs. Further, the invention provides a specific interferon alpha sequential regimen for treating cancers, especially those showing resistance to classical anti-proliferative chemotherapy drugs such as stem cell driven cancers. More specifically,... Agent: Ostrolenk Faber Gerb & Soffen

20100196322 - Polymer for tissue engineering applications and drug delivery: A biocompatible and biodegradable elastomeric polymer material, the polymer material comprising: glycerol and dodecanedioic acid, wherein the molar ratio of glycerol to dodecanedioic acid is from about 5:1 to about 1:5. Methods for using the biocompatible and biodegradable elastomeric polymer material comprises providing an PGD elastomeric polymer comprising glycerol and... Agent: Harness, Dickey & Pierce, P.L.C

20100196338 - Compositions and methods for treating cardiovascular disease: A fusion protein for treating cardiovascular disease includes a transcription factor (TF) and a cell-penetrating peptide (CPP). The fusion protein can be expressed from a cell that is delivered to the tissue being treated.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20100196335 - Methods and compositions for regulated expressions of nucleic acid at post-transcriptional level: The present invention provides an isolated nucleic acid comprising: a) at least one first nucleotide sequence encoding a heterologous nucleotide sequence of interest; and b) at least two second heterologous nucleotide sequences, wherein each second heterologous nucleotide sequences comprises: i) a first set of splice elements defining a first intron... Agent: Myers Bigel Sibley & Sajovec

20100196337 - Methods and compositions for stem cell self-renewal: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.... Agent: Kevin C. Hooper Bryan Cave LLP

20100196339 - Microparticle-based transfection and activation of dendritic cells: The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles, with the microparticles being comprised of biodegradable polymer and cationic detergent.... Agent: Novartis Vaccines And Diagnostics Inc.

20100196336 - Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods: Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered... Agent: Grant Anderson LLP C/o Portfolioip

20100196323 - Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof: The invention relates to a probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive, comprising a mixture of microorganisms, selected from the group Enterococcus faecium, DSM 16211, Lactobacillus reuteri, DSM 16350, Lactobacillus salivarius ssp. salivarius, DSM 16351, Pediococcus acidilactici, DSM 16210, Bifidobacterium animalis and DSM 16284.... Agent: Jacobson Holman PLLC

20100196340 - Lactid acid bacteria as priobiotic strains and compositions containing same: Useful probiotics have been selected among lactic acid bacteria strains of the genus L. acidophilus, L. crispatus, L. gasseri, L. helveticus and L. jensenii for their ability to kill urogenital and/or gastrointestinal pathogens and their ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within urogenital and/or gastrointestinal epithelial cells... Agent: Knobbe Martens Olson & Bear LLP

20100196341 - Novel lactobacillus paracasei subsp. paracasei sg96, a bacteriostatic composition containing the same and use thereof: A novel Lactobacillus paracasei subsp. paracasei SG96, a bacteriostatic composition containing the same and use thereof, comprise a novel Lactobacillus paracasei subsp. paracasei SG96 strain, wherein said strain had been deposited in China General Microbiological Culture Collection Center, CGMCC, accession number: CGMCC 2697, characterized in that said strain can inhibit... Agent: Schmeiser Olsen & Watts

20100196324 - Multifunctional cytokines: The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector... Agent: Buchanan, Ingersoll & Rooney PC

20100196325 - Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods: Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject for controlling viral titer, are provided. The combination of a therapeutic virus and chemotherapeutic agent can be used in methods of treating diseases, such... Agent: K&l Gates LLP

20100196334 - Cell suspension preparation technique and device: The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a... Agent: Proskauer Rose LLP

20100196329 - Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue: Disclosed herein is a cell therapeutic composition for treating ischemic limb diseases, more specifically, disclosed is a cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and sucrose or mannose as an excipient. The composition induces angiogenesis around closed blood vessels in the ischemic limb... Agent: Edwards Angell Palmer & Dodge LLP

20100196331 - Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions: Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier.... Agent: Biotech Beach Law Group , PC

20100196333 - Device and process for producing fiber products and fiber products produced thereby: The present invention is directed to a fiber, preferably bone fiber, having a textured surface, which acts as an effective binding substrate for bone-forming cells and for the induction or promotion of new bone growth by bone-forming cells, which bind to the fiber. Methods of using the bone fibers to... Agent: Morgan Lewis & Bockius LLP

20100196332 - Generation of brachial, thoracic and lumbar spinal motor neurons from embryonic stem cells in the absence of all-trans retinoic acid supplement: Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the... Agent: Cooper & Dunham, LLP

20100196328 - Ischemia-induced neovascularization is enhanced by hcns-sc transplantation: The invention provides methods for inducing or enhancing neovascularization following ischemia by transplanting an effective amount of human central nervous system stem cells. The human central nervous system stem cells can be grown as neurospheres or in adherent culture. Also provided are methods for inducing the repair of ischemic tissue... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100196326 - Method and system for biasing cellular development: Compositions and methods comprising siRNA targeted to APP mRNA are advantageously used to transfect stem cells and bias the cells against differentiating into glial type neural cells. The siRNA of the invention causes RNAi-mediated silencing of the APP mRNA. The inventors have discovered that expression APP induces gliogenesis, i.e., promotes... Agent: Timothy H. Van Dyke

20100196327 - Methods for diagnosing biological samples containing stem cells: The present invention relates to a method for diagnosing the compatibility of a biological sample containing stem cells from a donor with the immune system of a recipient. Furthermore, the present invention relates to a method for determining the quality of a stem cell preparation based on the inventive method,... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20100196330 - Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof: The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.... Agent: Darby & Darby P.C.

20100196342 - Mood, memory and cognitive function with pyridoxal 5'-phosphate: This invention relates to improvement of mood, memory and cognitive function with administration of pyridoxal 5′-phosphate. Also provided is the use of pyridoxal 5′-phosphate for the preparation of a medicament for the improvement of mood, memory and cognitive function, and kits comprising pyridoxal 5′-phosphate for the same purpose.... Agent: Merchant & Gould PC

20100196344 - Compositions and methods for treating pancreatic insufficiency: The present invention relates to compositions for the treatment of conditions, including pancreatic insufficiency. The compositions of the present invention comprise lipase, protease and amylase in a particular ratio that provides beneficial results in patients, such as those afflicted with pancreatic insufficiency. This invention also relates to methods using such... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100196343 - Compositions, methods, devices, and systems for skin care: Accordingly, a need has arisen for improved compositions, methods, devices, and systems for skin care including, without limitation, topical compositions and phototherapy devices and methods. A skin care method may comprise, in some embodiments, contacting at least a portion of the skin of a subject with a homogeneous, stable, self-foaming... Agent: King & Spalding LLP

20100196345 - Production of high mannose proteins in plant culture: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100196347 - Bone grafts with reduced protease activity and methods of selection and use: The invention features bone grafts (such as bone allografts) with reduced protease activity. These bone grafts are useful, for example, in conjunction with a polypeptide of interest (such as platelet derived growth factor) for treating, stabilizing, preventing, and/or delaying a bone, periodontium, ligament, cartilage, or tendon condition in an individual... Agent: Biomimetic Therapeutics Inc. C/o Mofo Palo Alto

20100196346 - Novel substrate for rpn 11 enzymatic activity: The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates.... Agent: Ropes & Gray LLP

20100196348 - Combination treatment with t-pa variant and low molecular weight heparin: The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g., AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life... Agent: Morrison & Foerster LLP

20100196352 - Composition for increasing stamina: Use of whey protein isolate in the preparation of a composition for increasing mean aerobic capacity, enhanced haemoglobin production, enhanced red blood cell production and increased mean corpuscular haemoglobin concentration in competitive species, such as equine species, involved in strenuous activity. The composition may further comprise a prebiotic such as... Agent: Jacobson Holman PLLC

20100196354 - Glutamate receptor antagonists and methods of use: The present invention relates to methods and compositions for modulating platelet activity by inhibiting or activating glutamate receptors. The invention further relates to preventing or treating thrombotic diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20100196355 - Immunophilin ligands and methods for modulating immunophilin and calcium channel activity: Immunophilin ligands and their uses as modulators of calcium channel activity are disclosed. Screening, therapeutic and prophylactic methods for conditions associated with calcium channel dysfunction, e.g., neurodegenerative and cardiovascular disorders, are also disclosed.... Agent: Wyeth LLC Patent Law Group

20100196353 - Intradermal hpv peptide vaccination: The invention relates to the use of a peptide derived from HPV-E2, E6 and/or E7 protein for the manufacture of a medicament for the treatment or prevention of an HPV related disease, wherein the medicament is for intradermal administration.... Agent: Edwards Angell Palmer & Dodge LLP

20100196357 - Microrna modulators and method for identifying and using the same: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20100196350 - Pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma: Disclosed herein are a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoiria, comprising a L1CAM activity inhibitor or expression suppressor and a treatment method using the composition. This is based on the finding that L1CAM is overexpressed on cholangiocarcinoma and plays an important role in the growth and... Agent: Knobbe Martens Olson & Bear LLP

20100196349 - Reeler domain containing protein: This invention relates to protein INSP 171, herein identified as containing a Reeler domain, and to the use of this protein and the nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100196351 - Secreted pate-like proteins: Novel PATE-like polynucleotides and polypeptides, are provided. Also described are splice-variants resulting in smaller polypeptides including five cysteine residues and capable of forming PATE-like polypeptide multimerse. The described polynucleotides were found to have a surprising expression profile, predominantly in the reproduction system and nervous system. Further provided are pharmaceutical compositions... Agent: The Nath Law Group

20100196356 - Tumour growth inhibitory compounds and methods of their use: Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and... Agent: Dla Piper LLP (us)

20100196363 - Cancer treatment combination therapy comprising vinflunine and trastuzumab: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab.... Agent: Birch Stewart Kolasch & Birch

20100196362 - Engineering fc antibody regions to confer effector function: The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function.... Agent: Edell, Shapiro & Finnan, LLC

20100196366 - Gefitnib sensitivity-related gene expression and products and methods related thereto: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor,... Agent: Sheridan Ross PC

20100196359 - Human monoclonal antibody human cd134 (ox40) and methods of making and using same: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100196358 - Method and kit to profile tumors by biomarker analyses including transcriptional factor assays: The present invention is related to a method and kit (or device) for the detection and/or the quantification of biomarkers related to tumorigenesis. Said method is advantageously used to propose or adapt an anti-tumoral therapeutic protocol to be administered to a subject. Furthermore, said method and kit (or device) are... Agent: Knobbe Martens Olson & Bear LLP

20100196361 - Method of inhibition of vascular development using an antibody: Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to... Agent: Mccarter & English, LLP Boston

20100196367 - Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies: The present invention relates to antibodies that bind to prorenin. In particular, the invention relates to monoclonal antibodies that bind to prorenin and inhibit the activation of prorenin. The antibodies of the invention are useful for screening for candidate agents that inhibit the activation of prorenin and candidate agents the... Agent: Fitzpatrick Cella Harper & Scinto

20100196369 - Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20100196364 - Monoclonal antibodies to fibroblast growth factor receptor 2: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20100196360 - Neutrokine-alpha and neutrokine-alpha splice variant: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically... Agent: Leydig, Voit & Mayer Ltd.

20100196368 - Substituted benz-azoles and methods of their use as inhibitors of raf kinase: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as... Agent: Novartis Vaccines And Diagnostics, Inc. Inc.

20100196365 - Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members: in the treatment of Epidermal Growth Factor Receptor (EGFR) family members dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for... Agent: Novartis Corporate Intellectual Property

20100196372 - Fcgammariib fusion proteins and compositions thereof: The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or... Agent: King & Spalding

20100196370 - Fusion protein of immunoglobulin fc and human apolipoprotein(a) kringle fragment: The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a... Agent: Moore & Van Allen PLLC

20100196373 - Intrathecal and intratumoral superantigens to treat malignant disease: The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating minors comprising (a) intratumoral... Agent: David Terman

20100196371 - Method of modulating the activity of functional immune molecules: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.... Agent: Sughrue-265550

20100196375 - Engineered scfv against bovine herpes virus type i: The present disclosure describes a single chain variable fragment (scFv) that binds BHV-1 virus comprising a light chain variable region, a linker and a heavy chain variable region. The disclosure also describes nucleic acid molecules encoding the scFv molecules, methods and uses thereof for treating or neutralizing BHV-1 infection and... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100196374 - Methods and compositions for treating autoimmune disease: The disclosure relates to OX-2/CD200 (herein referred to as CD200) antibodies and methods of treating autoimmune disease.... Agent: Ropes & Gray LLP

20100196376 - Method for reducing allergen-induced airway hyperresponsiveness: Disclosed is a method to reduce airway hyperresponsiveness, such as allergen-induced airway hyperresponsiveness, in a mammal by administering an agent that increases the biological activity of a CGRP receptor. Also disclosed are methods for identifying compounds useful in the present method.... Agent: Sheridan Ross PC

20100196384 - Anti-histone h1 monoclonal antibody and hybridoma for the production thereof: The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100196380 - Babesia subtilisin: Provided is an isolated and purified protein produced by a naturally occurring Babesia sp. comprising an amino acid sequence at least 90% identical to SEQ ID NO:1 and an isolated and purified nucleic acid encoding the above protein. Additionally provided is an isolated and purified nucleic acid comprising at least... Agent: K&l Gates LLP

20100196383 - Connective tissue growth factor (ctgf-3): The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20100196379 - Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides... Agent: Licata & Tyrrell P.C.

20100196377 - Methods of treating, diagnosing or detecting cancer: The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with LIV-1 overexpression.... Agent: Morrison & Foerster LLP

20100196382 - Nontypeable haemophilus influenzae virulence factors: The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes and the polypeptides encoded by these polynucleotide sequences. The invention also relates to a novel 110 kDa NTHi... Agent: Marshall, Gerstein & Borun LLP

20100196381 - P. ariasi polypeptides, p. perniciosus polypeptides and methods of use: Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments,... Agent: Klarquist Sparkman, LLP

20100196378 - Removal promoters and inhibitor for apoptosis cells in vivo: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk... Agent: Foley And Lardner LLP Suite 500

20100196387 - Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof: e

20100196386 - Ligands of hvem for treating hematologic malignancies and autoimmune diseases: The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.... Agent: Young & Thompson

20100196385 - Targeted binding agents directed to dll4 and uses thereof 524: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.... Agent: Medimmune, LLC Patrick Scott Alban

20100196388 - Targeted binding agents directed to sonic hedgehog homolog and uses thereof: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of... Agent: Medimmune, LLC Patrick Scott Alban

20100196389 - Methods of using corticotropin-releasing factor for the use of the treatment of cancer: Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).... Agent: Jones Day

20100196390 - Agonist anti-trkb monoclonal antibodies: The present invention provides TrkB agonist antibodies. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to improve nerve function, including treatment of peripheral neuropathies, such as Charcot-Marie-Tooth disease.... Agent: Pfizer Inc

20100196391 - Shigella ipad protein and its use as a vaccine against shigella infection: The present invention relates to compositions and methods for blocking entry of Shigella into a cell of an animal, to therefore providing protection against, or reduce the severity of Shigella infections. More particularly it relates to the use of the IpaD protein obtained from natural sources and/or through synthesis or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100196392 - Anti-system asc amino acid transporter 2 (asct2) antibody: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes... Agent: Sughrue-265550

20100196393 - Modulation of blood brain barrier protein expression: There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered.... Agent: Global Patent Group - Edi

20100196394 - Anti-cancer vaccine composition: Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single... Agent: Banner & Witcoff, Ltd.

20100196395 - Anti-igf antibodies: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100196396 - Compositions and methods for modulating ghrelin-mediated conditions: In certain aspects, the preproghrelin gene, but not the ghrelin receptor (GHS-R1a) is required for normal integration of thermoregulation and sleep in mice. Particular aspects provide methods for modulation of thermoregulation and other ghrelin-mediated conditions (e.g., reduction of appetite or food intake, reduction of body weight or treatment of obesity,... Agent: Davis Wright Tremaine, LLP/seattle

20100196397 - Five-helix protein: Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100196400 - Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods... Agent: Celera Corporation

20100196399 - Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions: LDL receptor-related proteins 1 and 2 (LRP-1 and LRP-2) and interaction between lactoferrin and LRP-1, LRP-2, or p42/44 MAP kinase in diagnosis and treatment of disorders such as bone or cartilage disorders. Also disclosed are methods of screening for related therapeutic compounds.... Agent: Fish & Richardson PC

20100196398 - Targeted binding agents directed to cd105 and uses thereof: The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of CD105 and as diagnostics.... Agent: Medimmune, LLC Patrick Scott Alban

20100196401 - Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products: Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100196402 - Method for predicting the response of a patient to treatment with an anti-tnf alpha antibody: The present invention relates to a method for predicting the response of a patient to treatment with an anti-TNFα therapy, in particular an anti-TNFα antibody, the method comprising: (a) providing an in vitro sample of T cells from the patient; (b) exposing said T cells to an anti-TNFα therapy; and... Agent: Clark & Elbing LLP

20100196403 - Antibody conjugates for circumventing multi-drug resistance: Conjugates of a cell permeability moiety coupled to an antibody against an intracellular epitope of a multi drug resistance (MDR) protein are provided. Also provided are pharmaceutical compositions that include these conjugates and methods for their use in preventing and inhibiting multi drug resistance to therapeutic agents, particularly to chemotherapeutic... Agent: Winston & Strawn LLP Patent Department

20100196405 - Glp-1 fc fusion protein formulation: The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders.... Agent: Eli Lilly & Company

20100196404 - Methods of use of the taci/taci-l interaction: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to... Agent: Immunex Corporation Law Department

20100196406 - Agents for the treatment of inflammatory diseases and methods of using same: A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100196408 - Metastatic colorectal cancer vaccine: The invention relates to prophylactic and therapeutic vaccines for protecting individuals against metastatic colorectal cancer and for treating individuals who are suffering from metastatic colorectal cancer.... Agent: Pepper Hamilton LLP

20100196407 - Tick galectin: A novel galectin, a polynucleotide encoding the same, a vector and a transformant comprising the polynucleotide, an antibody against the galectin, and a screening method for screening a substance capable of modifying the galectin, are disclosed. According to the galectin, polynucleotide, or vector, it is possible, for example, to exterminate... Agent: Sughrue Mion, PLLC

20100196409 - Basb006 polypeptides from neisseria meningitidis and immunogenic compositions thereof: The invention provides BASB006 polypeptides and polynucleotides encoding BASB006 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.... Agent: Seed Intellectual Property Law Group PLLC

20100196410 - Streptococcus pneumoniae antigens and vaccines: The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneumoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20100196411 - Yeast-based vaccine for inducing an immune response: The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting... Agent: Sheridan Ross P.C.

20100196412 - Homogeneous vaccine composition for the tumor treatment and its obtaining method: e

20100196413 - Use of yeast flakes for treating and/or preventing hyperinsulinemia: The invention relates to the use of yeast flakes for preparing a pharmaceutical composition for treating and/or preventing hyperinsulinemia.... Agent: Crowell & Moring LLP Intellectual Property Group

20100196414 - Silver ionized plant extraction liquid and use thereof: The present invention relates to silver-ionized plant extraction liquid and the use thereof. Particularly, there are provided herein a silver-ionized liquid extraction liquid prepared by ionizing silver in a plant extraction liquid used as an electrolyte and an antimicrobial composition comprising the same.... Agent: Intellectual Property Law Group LLP

20100196415 - Process for purifying guar: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the... Agent: Alcon

20100196416 - vaccine: A typhoid vaccine using heat shock protein (Hsp) of Salmonella typhi and a method for the manufacture thereof. A method of administering a composition comprising an effective amount of a complex consisting of a Hsp, in part or whole, either alone or covalently or non-covalently bound to an antigenic molecule,... Agent: Ladas & Parry LLP

20100196417 - Compositions comprising a b subunit of shiga toxin and a means stimulating nkt cells: The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical... Agent: Gottlieb Rackman & Reisman PC

20100196418 - Universal carrier for targeting molecules to gb3 receptor expressing cells: e

20100196419 - Enhancement of glycoprotein incorporation into virus-like particles: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100196420 - Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs: Immunogenic compositions and broad-spectrum vaccines containing newly identified isolates of canine distemper virus (CDV) collected from a geographic area are provided. The newly identified isolates exhibit attributes of both European wildlife lineage CDV and one or both of Arctic and American-2 lineage CDV. Therefore, the vaccines are broadly protective against... Agent: Fellers Snider Blankenship Bailey & Tippens

20100196421 - Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a... Agent: Nixon Peabody LLP - Patent Group

20100196422 - Novel polypeptides for isolating in vitro and preventing staphyloccocal infections on joint prostheses and other implanted foreign materials: The invention concerns novel polypeptides, or parts or variants of the novel polypeptides, the use of sequences encoding the polypeptides and the use of antibodies directed against the polypeptides in the field of in vitro diagnosis of a Staphylococcus epidermidis and/or Staphylococcus aureus infection on foreign material implanted in the... Agent: Young & Thompson

20100196423 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent: K&l Gates LLP

20100196427 - Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage: The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100196425 - Oros push-stick for controlled delivery of active agents: A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release... Agent: Paul D. Yasger Abbott Laboratories

20100196424 - Stabilization of long chain polyunsaturated oils: Compositions that include an oxidizable fatty acid-containing oil and wax capable of limiting oxidation of the oil are disclosed. Also disclosed are compositions that include an ingestible fatty acid-containing oil and an ingestible wax. Polyunsaturated fatty acid-containing oils may be stabilized by mixing the oil with a melted wax capable... Agent: Gary C. Cohn, PLLC

20100196426 - Use of microvesicles in diagnosis and prognosis of medical diseases and conditions: The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject.... Agent: David S. Resnick

20100196428 - Method for producing cosmetic preparations: The present invention relates to a method for producing cosmetic preparations comprising metal oxide, where the reaction mixture which forms during the production of the particulate metal oxide is incorporated into the cosmetic preparations essentially without further work-up.... Agent: Connolly Bove Lodge & Hutz, LLP

20100196429 - Oil-in-water emulsion composition and method for producing the same: The present invention provides: an oil-in-water emulsion composition, into which an oil-soluble drug is stably incorporated and which is excellent in feeling during use; and a method for producing the aforementioned composition, which does not require complicated operations. An oil-in-water emulsion composition comprising; (A) a polyoxyethylene phytosterol, (B) a glycerin... Agent: Rankin, Hill & Clark LLP

20100196430 - Controlled-released agricultural chemical formulation: An object of the present invention is to provide an agricultural chemical formulation which is able to control release of an agricultural chemical active ingredient. This agricultural chemical formulation includes a composition, containing an agricultural chemical active ingredient, styrene-maleic anhydride copolymer or mixture of styrene-maleic anhydride copolymer and polymer having... Agent: Oliff & Berridge, PLC

20100196431 - Granule coated with urethane resin: A coated granule is obtained by coating a bioactive substance-containing granule with a urethane resin obtained by reaction of an aromatic diisocyanate with a polyol mixture containing a polyesterpolyol and a C2-C8 polymethylene glycol, wherein the molar ratio of the polyesterpolyol to the polymethylene glycol is 1:20 to 20:1. The... Agent: Panitch Schwarze Belisario & Nadel LLP

20100196432 - Biopolymer structures: The invention described herein relates to biopolymer structures. The biopolymer structures are spatially organized from the nanometer to centimeter length scales and incorporate functionally active cells. Applications of the biopolymer structures include use with stem cells.... Agent: Mccarter & English, LLP Boston

20100196433 - Prevascularized devices and related methods: The present invention provides an implantable devices for providing a biologically active agent to a subject in need thereof, the device comprising a microvessel construct in contact with a biocompatible, semi-permeable pouch, the pouch encapsulating a cell or cells capable of producing the biologically active agent. The present invention also... Agent: Nixon Peabody LLP

20100196434 - Combined fibnrinolytic and antimicrobial cathether and uses thetherof: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.... Agent: Amster, Rothstein & Ebenstein LLP

20100196436 - Implants containing disulfiram and an anti-inflammatory agent: The present invention provides an implantable composition which contains disulfiram, an anti-inflammatory agent, and optionally a pharmaceutically acceptable carrier. Methods of making the implants, and methods of using the implants to treat alcoholism and opioid dependency are also disclosed.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100196435 - Materials and methods for delivering compositions to selected tissues: This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100196437 - Medical devices having a surface including a biologically active agent therein: The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100196438 - Methods including medical devices having a surface including a biologically active agent therein: The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100196439 - Angiogenesis mechanism and method, and implantable device: Various methods and devices are provided for providing therapy to a living body. In one embodiment, an implanted permeable container has living cells provided therein, and various nutrients and/or agents are provided into the container to promote cell life.... Agent: Medtronic, Inc.

20100196440 - Implant material: The present relates to the field of dental and bone surgery. In particular, the invention relates to fibrous pharmaceutical compositions; fibrous webs, yarns and woven fabrics of such pharmaceutical compositions; to implant material essentially consisting of fibrous pharmaceutical compositions; to the manufacturing and use of such fibers/webs/implant materials.... Agent: Marshall, Gerstein & Borun LLP

20100196442 - Methods for treating open wounds: A method for treating an open wound, such as a surgical wound, may include preparing a first composition including a platelet poor plasma (PPP), and preparing a second composition including a platelet rich plasma (PRP). A layer of the first composition may be applied within the open wound, and a... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20100196441 - Uses of immunologically modified scaffold for tissue prevascularization cell transplantation: This invention provides method of making and using of a porous 3 dimensional cyclic RGD peptide-modified alginate scaffold that can be loaded with different cell types and/or growth factors for implantation at sites of tissue damage to promote tissue regeneration. The cyclic RGD peptide promotes vascular formation of the host... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100196443 - Use of cordyceps species or extract thereof in the egg production: A dietary supplement or animal feed includes at least one Cordyceps species or extract thereof. The dietary supplement and/or animal feed is preferably for oviparous animals and in particular for the production of eggs.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100196444 - Devices with cells cultured on flexible supports: Methods and compositions provide suitable support material for culturing cells with a desirable metabolic activity. For example, keratinocytes directly grown on flexible supports show metabolic activity. Wound healing methods and compositions using the cells grown on flexible supports, wherein the cells exhibit increased metabolic activity are disclosed.... Agent: Barnes & Thornburg LLP

20100196446 - Drug delivery and substance transfer facilitated by nano-enhanced device having aligned carbon nanotubes protruding from device surface: The present invention relates to a nano-enhanced device for substance transfer between the device and a tissue. The device comprises a substrate with substantially aligned carbon nanotubes anchored within the substrate, and with at least one end of the carbon nanotubes protruding from the substrate. The protruding nanotube ends may... Agent: Tope-mckay & Associates

20100196447 - Silk biomaterials and methods of use thereof: The present invention provides an all-aqueous process and composition for production of silk biomaterials, e.g., fibers, films, foams and mats. In the process, at least one biocompatible polymer, such as poly(ethylene oxide) (PEO) (a well-documented biocompatible material), was blended with the silk protein prior to processing e.g., electrospinning. We discovered... Agent: David S. Resnick

20100196445 - Systems and methods for delivery of biologically active agents: The invention provides methods and devices for the delivery of therapeutic or biologically active agents to tissue, for example by facilitating the transport of said agents through the skin of a human or animal. Therapeutic agents include various botulinum neurotoxin (BoNT) and other biologically active agents, which can be delivered... Agent: Wilson, Sonsini, Goodrich & Rosati

20100196448 - Wound healing dressing and methods of manufacturing the same: Disclosed are a hydrogel dressing for covering or treating a wound and a method for preparing the same. The hydrogel dressing includes a matrix structure of a cross-linked mixture, and an elastic sheet coated with an elementary metal or ionic metal embodied in the matrix structure. The mixture comprises a... Agent: Knobbe Martens Olson & Bear LLP

20100196449 - System and method to improve sensory function: A system and method to improve sensory functions in the hand or foot by dermal topical application of a local anaesthetic substance to adjacent skin areas, using a tailored application device or kit specially designed to fit the size and anatomical shape of the body part which is to be... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100196457 - Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence: s

20100196453 - Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition,... Agent: King & Spalding LLP

20100196455 - Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods of use thereof: The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100196454 - Dressing formulations to prevent and reduce scarring: Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible... Agent: Morrison & Foerster LLP

20100196456 - Emulsion preconcentrates and micellar formulations containing wood resins: The invention relates to micelles and emulsion preconcentrates comprising i) one or more active ingredients and ii) wood resin, optionally in combination with gum arabic, and iii) optionally additional adjuvants; products containing said micelles and/or emulsion preconcentrates, method for the production of micelles, emulsion preconcentrates, and products.... Agent: Ladas & Parry LLP

20100196460 - Integrated photoactive agents for real-time monitoring of hemostasis: The present invention discloses a number of photoactive compounds designed to bind and inhibit serine proteases. Compounds disclosed herein may be utilized in a number of appropriate medical diagnostic and/or therapeutic procedures such as the monitoring of hemostasis, imaging and/or treatment of vulnerable plaques, and/or tumor imaging and/or treatment.... Agent: Mallinckrodt Inc.

20100196458 - Modified cytokines for use in cancer therapy: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.... Agent: Foley And Lardner LLP Suite 500

20100196452 - Pharmaceutical compositions and methods for treating erectile dysfunction: The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.... Agent: Sughrue Mion, PLLC

20100196461 - Resuscitation fluid: A method for treating conditions related to lack of blood supply with a resuscitation fluid is disclosed. The resuscitation fluid contains a lipophilic component and a polar liquid carrier. The lipophilic component forms an emulsion with the polar liquid carrier. The resuscitation fluid can be used to increase the blood... Agent: Andrews Kurth LLP

20100196450 - Targeting pax2 for the induction of defbi-mediated tumor immunity and cancer therapy: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding... Agent: Morris Manning Martin LLP

20100196459 - Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.... Agent: Burr & Brown

20100196451 - Vaccines containing non-live antigenic vectors: The present invention provides a vaccine composition comprising a non-live vector which targets the MHC class I pathway derived from a bacterial toxin or an immunologically functional derivative thereof but excluding those which bind the Gb3 receptor complexed with at least one first antigen and further comprising at least one... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100196462 - Method for manufacturing a pharmaceutical form of oseltamivir phosphate: e

20100196463 - Methods and compositions for reduction of side effects of therapeutic treatments: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a... Agent: Wilson, Sonsini, Goodrich & Rosati

20100196464 - Orlistat pharmaceutical formulations: Solid pharmaceutical formulations are prepared using compositions comprising orlistat and having average particle sizes less than about 250 μm.... Agent: Dr. Reddy''s Laboratories, Inc.

20100196466 - Drug delivery system: A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from... Agent: Hunton & Williams LLP Intellectual Property Department

20100196465 - Stable pharmaceutical composition of a water-soluble vinorelbine salt: A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water-soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet.... Agent: Birch Stewart Kolasch & Birch

20100196467 - Therapeutic combination of amlodipine and benazepril/benazeprilat: s

20100196468 - Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt: Stable pharmaceutical composition consisting of a hydrosoluble vinflunine salt and at least one diluent and one lubricant, said composition being in the form of a solid intended for oral administration. The hydrosoluble vinflunine salt is preferably Vinflunine ditartrate. The pharmaceutical composition is advantageously in the form of a capsule or... Agent: Birch Stewart Kolasch & Birch

20100196469 - Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof: The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression.... Agent: Akc Patents

20100196470 - Device and method for reducing calorie intake: Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach 10 and/or anywhere else in the gastrointestinal (GI) tract, absorbing or encapsulating the captured food into multiple capturing members and moving such multiple capturing members containing the ingestible encapsulated... Agent: Levine Bagade Han LLP

20100196472 - Modified release compositions of milnacipran: A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a Tmax of 4-10 hours.... Agent: Hunton & Williams LLP Intellectual Property Department

20100196471 - Novel tablet dosage form: The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100196473 - Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release: Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro... Agent: Crowell & Moring LLP Intellectual Property Group

20100196474 - Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period... Agent: King & Spalding LLP

20100196475 - Controlled release tablet formulation containing magnesium aluminometasilicate: The present invention relates to a controlled pharmaceutical dosage forms for oral administration, and in particular to the excipients used to prepare such medicaments. For example, a dosage form for oral administration is provided consisting of a minimum of 15% w/w of magnesium aluminometasilicate, one or more pharmaceutically active agents... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100196476 - Process for the preparation and pharmaceutical formulations for 4-quinolinones and quinolines and use thereof: The present invention describes novel 4-quinolinones corresponding to formula (I) and quinoline derivatives thereof as formula (II), process of preparation thereof, pharmaceutical formulations comprising said 4-quinolinones and pharmaceutical application thereof for diseases related to disorders of white blood cells, such as inflammatory and autoimmune diseases, including rheumatism, as well as... Agent: Arent Fox LLP

20100196477 - Dry mouldable drug formulation: Solid pharmaceutical compositions and methods of making and administering for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100196480 - Graft materials containing bioactive extracellular matrices and cells: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20100196479 - Methods and compositions comprising at least one alpha3 beta4 nachr antagonist or pharmaceutically acceptable salt thereof: The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one α3 β4 nAChR antagonist and formulations comprising at least one α3 β4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100196478 - Protein matrix materials, devices and methods of making and using thereof: The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20100196482 - Polymer-encapsulated reverse micelles: A method for encapsulating nucleic acids, particularly siRNAs, shRNAs, microRNAs, gene therapy plasmids, and other oligonucleotides in biodegradable polymers is disclosed, whereby the nucleic acids are formulated into reverse micelles composed of non-toxic and/or naturally-occurring lipids prior to nanoparticle formation by nanoprecipitation. This method can be coupled to other techniques... Agent: Pabst Patent Group LLP

20100196481 - Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve... Agent: Volpe And Koenig, P.C.

20100196489 - Bone growth particles and osteoinductive composition thereof: A biocompatible synthetic bone growth composition comprising a fibrillar collagen component and a calcium phosphate component. The composition is formed into particles, and then formed into a unitary article that may be provided at the site of a skeletal defect. An osteoinductive component may be further added, either before or... Agent: Wood, Herron & Evans, LLP (zimmer)

20100196487 - Composition with antimicrobial effect: A composition with antimicrobial efficacy has at least one or more polymers; or polymerizable or crosslinkable monomers; or polymerizable or crosslinkable prepolymers; or polymerizable or crosslinkable polymers; and porous glass particles which contain an antimicrobial silver additive.... Agent: Lerner Greenberg Stemer LLP

20100196490 - Compositions and methods of delivery of pharmacological agents: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of... Agent: Morrison & Foerster LLP

20100196483 - Method for treatmentof severe and uncontrollable asthma: A method for treatment of severe and uncontrollable asthma by providing means for delivery of high doses of a suitable inhalable corticosteroid directly to the small airways of the lower lungs with substantial decrease in need for simultaneous administration of oral corticosteroids and with a significant reduction in undesirable secondary... Agent: Peters Verny , L.L.P.

20100196486 - Methods for producing aripiprazole suspension and freeze-dried formulation: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 μm, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g.,... Agent: Sughrue Mion, PLLC

20100196488 - Pharmaceutical formulation: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein... Agent: Wolf Greenfield & Sacks, P.C.

20100196485 - Rare earth metal compounds, methods of making, and methods of using the same: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100196484 - Use of expanded amorphous mineral particles for increasing the tenacity of a fragrance, scenting composition and method for treating body odours: r

20100196492 - Electrostatic coating of particles for drug delivery: A system for electrostatically coating particles is provided. The system is particularly well suited for coating charged drug delivery particles (e.g., nanoparticles, microparticles) with a coating of opposite charge. The coating may include a targeting moiety such as a small molecule ligand, peptide, protein, aptamer, etc. The coated particles are... Agent: Wolf Greenfield & Sacks, P.C.

20100196494 - Enhanced antimicrobial activity compositions of blends of plant essential oils: Antimicrobial compositions based on a combination or blend of plant essential oils is of enhanced antimicrobial effectiveness; by adding to the combination of at least two plant essential oils, and preferably adds a small but antimicrobial enhancing effective amount of an enhancer selected from the group consisting of polyionic organic... Agent: Mckee, Voorhees & Sease, P.L.C

20100196493 - Method for producing stable powder compositions: The invention relates to the use of at least one viscous compound, the viscosity of which is greater than 5 Pa·s−1, to substantially prevent the degradation of a substance sensitive to temperatures of 20° C. to 100° C. and/or pressures of 106 to 107 Pa and/or a relative humidity of... Agent: Young & Thompson

20100196491 - Protein vaccines against poxviruses: The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having... Agent: Elizabeth Arwine, Esq. U.s. Army Medical Research And Materiel Command

20100196495 - Delivery of flu antibodies to surfaces in contact with air: The invention relates to a method, composition and inhaler system for treatment or prophylaxis of influenza infection in one or more subjects by applying to a surface selected from air filters, sick room surfaces and respiratory mucosal membranes at least one immune material selected from antibodies and fragments thereof which... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100196496 - Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100196497 - Method of treating tissue using platelet-rich plasma in combination with low-level laser therapy: This invention is a method of treating a patient's injured tissue by applying platelet-rich plasma and laser energy to the injured tissue. The applied energy is low-level, and the patient feels no sensation of the low-level laser energy being applied. The laser energy can be applied before, after, or during... Agent: Etherton Law Group, LLC

20100196498 - Emulsion hydro therapy or milk therapy for treatment of psoriasis: It is an object of the Invention furnish a method for treatment of psoriasis at the human body for the purpose of healing this disease by way of bacteriophages. The treatment of the psoriasis patient is performed with a whole bath. The bath liquid comprises 95 percent water and 5... Agent: Horst M. Kasper

20100196499 - Xenograft bone matrix for orthopedic applications: The invention provides for the use of an improved xenograft bone particulate with respect to osteo-integration and bone remodeling, while diminishing the primate-to-pig immunological response using established bone-processing technique. Work was carried out using undecalcified bone to determine immunocompatibilty and bone remodeling potential of processed porcine bone struts following onlay... Agent: Gunn, Lee & Cave, P.C.

20100196500 - Anhydrous dicalcium phosphate particles and production method thereof: e

20100196501 - Silver-containing foam structure: A method of producing a hydrophilic polyurethane foam structure containing a silver salt, chosen from the group of silver sulphate, silver citrate, silver acetate, silver carbonate, silver lactate and silver phosphate, or a mixture of these salts includes the steps of (a) providing a water phase containing a surfactant, and... Agent: Young & Thompson

20100196502 - Isoform selective hdac inhibitors: One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100196503 - Low odor, hard surface sporicide: A low odor, liquid disinfectant composition comprising multiple components, which, upon mixing, provide an aqueous solution comprising low levels of peracetic acid for use in decontaminating articles and surfaces contaminated with bacteria, viruses, fungi and other biological contaminants such as spores, including, but not limited to, Clostridium difficile (C.diff). The... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20100196505 - Low odor, hard surface sporicides and chemical decontaminants: A low odor, liquid disinfectant composition comprising multiple components, which, upon mixing, provide an aqueous solution comprising low levels of peracetic acid for use in decontaminating articles and surfaces contaminated with bacteria, viruses, fungi and other chemical and biological contaminants including, but not limited to, spores, such as Clostridium difficile... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20100196504 - Synergistic active preparations comprising 1,2-decanediol and further antimicrobial active compounds: l

20100196506 - Preparation of a pyrithione salt dispersion usable in urethane applications: The present invention relates to a stable pyrithione salt polyol dispersion containing a pyrithione salt(s) in particulate form, a polyol and a stabilizer such as a rheological additive. The dispersion can be incorporated into existing polyurethane formulations without additional formula adjustment. Polyurethane foams produced from the composition containing pyrithione salt... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100196507 - Treatment of wounds and compositions employed: A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.... Agent: Spencer Fane Britt & Browne LLP

20100196508 - Method and composition for supplementation of nutritional deficiencies in renal patients: The present invention relates to compositions and methods for treating the nutritional deficiencies observed in patients suffering from renal disease and associated disorders. Specifically, the method involves administering to a renal patient a composition comprising vitamin C, vitamin E, B-complex vitamins, selenium, and zinc.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100196511 - Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer: This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective amount of one or more chemotherapeutic agents.... Agent: Seed Intellectual Property Law Group PLLC

20100196510 - Composition and treatment: Disclosed are compositions for the treatment of neuropathy and in particular peripheral neuropathy. The compounds include low molecular weight glycosaminoglycans. The peripheral neuropathy may be due to cancer treatment drugs.... Agent: Knobbe Martens Olson & Bear LLP

20100196509 - Methods for diagnosis and treatment of endometrial cancer: The present invention discloses methods of using endothelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs).... Agent: Dla Piper LLP (us)

20100196512 - Treatment of non-oral biological tissue with chlorine dioxide: Methods, devices, compositions, and systems for the alleviation of non-oral biological tissue infections by administration of chlorine dioxide are provided.... Agent: Basf Catalysts LLC

20100196513 - Colon cleansing compositions and methods: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate,... Agent: Leon R. Yankwich

20100196514 - Calcium silicate-based composite cement and methods for the preparation: The present invention provides a method for producing calcium silicate-based bone cement and a composition produced by the method. It further provides a novel composition for bone tissue repair.... Agent: Wpat, PC Intellectual Property Attorneys

20100196515 - External preparation for skin: e

20100196516 - Treatment of infections by carbon monoxide: The invention relates to the use of carbon monoxide (CO) to treat infections. The invention also provides novel carbon monoxide releasing molecules (CORMs).... Agent: Wolf Greenfield & Sacks, P.C.

20100196517 - Topical delivery of a nitric oxide donor to improve body and skin appearance: This invention generally relates to improvement of the body and skin appearance, for example enhancing the appearance of sagging, wrinkled, or cellulite-afflicted areas of the skin and body, through the local delivery of a nitric oxide donor, for example, using delivery vehicles such as lotions, creams, liquids, and/or transdermal patches.... Agent: Wolf Greenfield & Sacks, P.C.

20100196518 - Method and device for the treatment of water for purposes conducive to good health: This invention therefore presents a method and a device for the treatment of drinking water for purposes conducive to good health and the production of wellness and healthcare products. In this method the water to be treated is heavily swirled within a container (10). Using a rotor (50) with at... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100196519 - Citrus fruit fibers in emulsions: The current invention relates to a composition of citrus fruit fibers and hydrophobic vitamin. The hydrophobic nutritional supplement is selected from the group consisting of vitamin A, D, E, K, and mixtures thereof. It further relates to a process for preparing liquid compositions comprising said citrus fruit fibers and hydrophobic... Agent: Fish & Richardson P.C.

20100196521 - Formulation for the treatment of hypoxia and related disorders: A plant extract formulation is described comprising lemon oil, eucalyptus oil, basil oil, davana oil, rosewood oil, fennel oil and citronella oil. The formulation is used for the treatment of hypoxia and related disorders.... Agent: EagleIPLimited

20100196520 - Insect repellent formulations: An insect repellent aqueous formulation comprising a combination of at least two essential oils, citrus peel tincture, and vinegar. A method of preparing an insect repellent aqueous formulation comprising: Mixing a combination of essential oils with an emulsifier and citrus tincture; Adding to the mixture obtained in (a) distilled water... Agent: Dr. D. Graeser Ltd.

20100196522 - Compositions containing amines and use thereof:

20100196523 - Flower remedy beverage and method of making: A beverage and method of preparing a beverage comprising various combinations of flower essences designed for human consumption to treat emotional, mental and physical illnesses while providing hydration. In one illustrative embodiment of the method herein, a beverage is first formed by mixing a flower essence tincture with a diluent.... Agent: Leonard Tachner, A Professional Law Corporation

20100196524 - Novel peptides and methods for producing them: The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to novel peptides, pilus structures, polynucleotides as well as vectors, host cells, products and pharmaceutical compositions comprising the polynucleotides, peptides or pilus structures. The invention also relates to gene clusters... Agent: Nixon & Vanderhye, PC